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ABSTRACT 
Depression and stimulant drug addiction each result in massive losses of health, 
productivity and human lives every year.  Despite decades of research, current treatment 
regimes for depression are ineffective in approximately half of all patients.  Therapy 
available to stimulant drug addicts is largely ineffective and moreover, dedicated 
treatments for drug dependence (including abuse of cocaine) are non-existent.  Thus, 
there is a pressing need to further understanding of the molecular mechanisms underlying 
these disorders in order to develop novel, targeted therapeutic strategies. 
Chromatin remodeling, including changes in histone acetylation, has been 
proposed to play a role in both the etiology and treatment of depression and stimulant 
abuse.  Histone acetyltransferases (HATs) and histone deacetylases (HDACs) regulate 
numerous cellular processes, including transcription, cell cycle progression and 
differentiation.  Moreover, histone acetylation has been shown to regulate hippocampal 
neurogenesis, a cellular response associated with the pathogenesis and treatment of 
depression and stimulant abuse (Hsieh et al., 2004, Yamaguchi et al., 2004, Fischer et al., 
2007).  Ultimately, such basic cellular processes impact higher order function, namely 
cognition and emotion.   
Indeed, recent studies suggest that HDAC activity in selected forebrain regions, 
including ventral striatum and hippocampus, modulate stimulant- and antidepressant-
induced behavior (Kumar et al., 2005, Tsankova et al., 2006a, Fischer et al., 2007).  
These reports highlight an association between chromatin remodeling and diverse 
behavioral changes, including changes induced by the pleiotropic HDAC inhibitor, 
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sodium butyrate (SB), (Kumar et al., 2005, Tsankova et al., 2006a, Fischer et al., 2007).  
However, behavioral, brain-metabolic and molecular effects of SB treatment in the 
context of rodent models of depression, dopaminergic sensitization and repeated cocaine 
administration remained unclear. 
The work described in this thesis illustrates the potential for chromatin modifying 
drugs in mechanisms underlying the experimental pharmacology of depression and 
stimulant addiction.  Specifically, the data presented here support the view that treatment 
with the short chain fatty acid, sodium butyrate enhances: 
(1) antidepressant-like behavioral effects of the selective serotonin reuptake 
inhibitor (SSRI), fluoxetine  
(2) locomotor sensitization induced by repeated administration of the dopamine 
D1/D5 receptor agonist SKF82958; and 
(3) brain metabolic activation upon repeated cocaine administration as evidenced 
by fMRI in awake rats.   
Furthermore, this report provides evidence that these treatment paradigms will 
result in chromatin modification changes associated with active transcription, in addition 
to increased mRNA levels of plasticity-associated genes, including brain-derived 
neurotrophic factor (BDNF) at key brain regions implicated in the pathogenesis of 
depression and stimulant addiction. 
  To date, little is known regarding the underlying mechanisms of action mediating 
the enhancing effects of sodium butyrate on the various antidepressant- and stimulant-
related paradigms.  Our findings underscore the potential of chromatin-modifying drugs 
vi 
to profoundly affect the behavioral response of an animal to antidepressant and stimulant 
drugs and warrants consideration in the context of developing novel therapeutic 
strategies.   
vii 
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CHAPTER I: General Introduction 
Depression: Overview 
Described by Hippocrates more than 2400 years ago, ‘melancholia,’ now 
depression, is a mood disorder affecting nearly one of every six people in the U.S. 
(Wittchen et al., 1994, Murray and Lopez, 1997, Pincus and Pettit, 2001, Nestler et al., 
2002, Greenberg et al., 2003, Kessler et al., 2003, Stewart et al., 2003).  Yearly, 
depression causes a loss of $100 billion in the U.S. alone through decreased productivity 
and treatment-related costs (Wittchen et al., 1994, Murray and Lopez, 1997, Pincus and 
Pettit, 2001, Greenberg et al., 2003, Kessler et al., 2003, Stewart et al., 2003).  Moreover, 
the loss of human life remains a solemn reality as suicide rates in depressed patients are 
estimated as high as 15%. (Michelson et al., 1996, Musselman et al., 1998, Ciechanowski 
et al., 2000, Schulz et al., 2000).  The focus of this section is to provide an overview of 
depression including proposed pathophysiology, treatment and current tools for 
depression research. 
Etiology of Depression 
The presence of a genetic component in the pathoetiology of depression has been 
recognized, even two millennia ago, based on the observation that the disorder aggregates 
in families.  More formal behavioral genetic studies have established that the 
concordance rate of depression in monozygotic twins approaches 40-50%, indicating this 
proportion of the disease is hereditary in nature (Nestler et al., 2002).  Moreover, a 
number of genetic association studies have yielded intriguing data.  A recent meta-
analysis found a significant association of six susceptibility genes with depression: 
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APOE, the dopamine D4 receptor, the dopamine and serotonin transporter, MTHFR, and 
the β subunit of G proteins (Lopez-Leon et al., 2007).  However, one of the major 
limitations in the study and development of effective treatment of mood disorders 
remains the lack of definitive genetic mutations that cause depression.   
More recently, human postmortem studies employing microarray technology have 
underscored the enormous complexity of transcriptional changes associated with 
depression.   For example, a recent small-scale study revealed a subset of genes whose 
expression was increased in the dorsolateral prefrontal cortex of patients with major 
depressive disorder.  Interestingly, these genes function in stress response (UCN3, CNR2) 
and transcriptional regulation (FOXD3, YWHAH and FBXL10) (Kang et al., 2007).  
However, it remains to be clarified as to which of these alterations in gene expression 
represent primary/hereditary deficits, which represent compensatory changes and which 
are due to environmental factors.  As will be highlighted in subsequent sections, 
environmental factors (such as stress), in conjunction with hereditary genetic deficits, are 
believed to play a major role in the alterations in transcriptional regulation thought to 
underlie the pathophysiology of depression.  
Environmental factors, particularly emotional stress, are strongly associated with 
depression.  While it is clear that the context and magnitude of stressful stimuli sufficient 
to induce depression varies greatly between individuals, the relationship between 
emotional stress and depressive episodes has been established (Nestler et al., 2002).  
Postmortem brain studies of depressed individuals revealed dramatic physiological 
differences from non-depressed control brains including neuronal atrophy and cell loss in 
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limbic brain structures (Manji et al., 2001, Manji and Duman, 2001, Duman and 
Monteggia, 2006).  Importantly, exposure of animals to environmental stress is sufficient 
to induce depressive-like behavioral changes in addition to cellular deficits mirroring 
those seen in postmortem brain (Duman, 2004a).  Nonetheless, both genetic and 
environmental factors are likely to involve common brain regions and molecular 
pathways.  Delineation of these individual regions and pathways will help to refine our 
current understanding of underlying causal mechanisms, and will thus aid in the 
development of novel, targeted treatments for mood disorders. 
 
Brain regions affected 
Given the complex nature of depression, it is not surprising that current 
information regarding the specific brain regions underlying the disease is limited.  While 
pathological changes have been observed in the brains of depressed patients, these 
findings are not categorical, and as such do not represent bona fide biomarkers for the 
disease.  Postmortem- and structural imaging comparisons have revealed decreased gray 
matter volumes in subregions of cortex (including prefrontal cortex, PFC), amygdala, 
hypothalamus and hippocampus (Ongur et al., 1998, Rajkowska et al., 1999, Drevets, 
2000, Rajkowska, 2000, Manji et al., 2001, Manaye et al., 2005).  These results are 
supported by neuroimaging studies showing alterations in cerebral blood flow and 
glucose metabolism in areas of the prefrontal cortex (PFC), hippocampus, striatum, 
amygdala and thalamus (Manji et al., 2001, Berton and Nestler, 2006, Mah et al., 2007). 
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Consideration of the normal functions of these regions draws potential 
relationships to specific emotional symptoms of depression.  Reward pathways involving 
the striatum and amygdala are likely core in mediating depression-associated anhedonia, 
anxiety and reduced motivation.  The hypothalamus may play a role, as imbalances in 
sleep, appetite and energy in addition to loss of interest in pleasurable activities are 
prevalent in affected individuals (Nestler et al., 2002).  Cognitive and emotional behavior 
aspects, including memory impairments and feelings of worthlessness, hopelessness, 
guilt, doom and suicide may be controlled by the frontal cortex and hippocampus. 
Moreover, connections between these regions via major neurotransmitter pathways 
highlight putative brain circuitry involved in the pathogenesis and treatment of mood 
disorders (Nestler et al., 2002, Berton and Nestler, 2006) (Fig.1-1).  Furthermore, while 
knowledge of the neuropathology of the depressed brain has come from postmortem 
examination, much has been determined by comparing the molecular changes evident 
following effective antidepressant treatment.   
 
Treatment of Depression 
Currently, a variety of treatment options for depressed patients provide tools for 
controlling symptoms in 60-70% of affected individuals.  Interventions as simple as 
increased exercise are part of a battery of non-chemical therapeutic methods also 
including psychotherapy and electro-convulsive shock therapy (Dunn et al., 2005, Berton 
and Nestler, 2006).  However, the most common form of treatment is antidepressant drug 
therapy.   
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As a class of drugs, antidepressants are prescribed more than any other type of 
medication (Cherry, 2007).  Interestingly, since the serendipitous discovery of first-
generation antidepressants in the 1950’s (the tricyclics and monoamine oxidase 
inhibitors), little has changed in the design of antidepressant drugs.  Early observations of 
the acute targets of these compounds revealed that they non-specifically inhibited the 
dopamine-, serotonin-, and norepinephrine-transporters or the monoamine oxidases 
(Frazer, 1997, Nestler et al., 2002). Details of these mechanistic actions revealed an 
increase in neurotransmitter signaling and led to the monoaminergic hypothesis of 
depression.  This hypothesis states that a key cause of mood disorder is a disregulation of 
catecholamine and serotonin transporters, in addition to abnormalities in the catabolism 
of monoamine neurotransmitters (Park et al., 2005, Berton and Nestler, 2006). 
Improvements in the non-specific activity of first-generation drugs led to selective 
reuptake inhibitors for serotonin or norepinephrine (SSRI / SNRI), second-generation 
antidepressants which remain widely used.  Based on the popularity and general 
effectivity of these prototypic drugs, current antidepressants are almost exclusively 
monoamine-targeting (Berton and Nestler, 2006). 
However, critics point out that although current drugs are safer than their 
predecessors, the improvements in efficacy and side-effect profiles have been considered 
marginal (Berton and Nestler, 2006). Additionally, these drugs have a huge placebo 
effect; 50% of people respond to antidepressants, but 30% respond to placebo (reviewed 
by (Rihmer, 2007).  Furthermore, many patients who initially obtain pharmaceutical 
relief from their depression, after months without symptoms, cease treatment.  Often, 
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these patients then relapse into a more severe state of depression (Bockting et al., 2008).  
Thus, there exists a pressing need to develop advanced, mechanism-based antidepressants 
for both controlling and maintaining relief from depression.   
In recent years, focus has been drawn to the delay in therapeutic efficacy in 
patients taking antidepressant drugs.  That weeks or months of treatment are required for 
any therapeutic effect suggests that protein expression changes, receptor sensitization 
and/or cellular changes underlie the action of these drugs (Nelson, 1999, Nestler et al., 
2002, Zarate and Quiroz, 2003, Geddes et al., 2004, Wong and Licinio, 2004, 
Montgomery, 2006).  While the monoaminergic hypothesis could account for this, it has 
been proposed that the mechanisms of antidepressant action in humans involve gene 
expression changes that correct for underlying transcriptional dysregulation, which, in 
turn, rectify altered protein levels, and ultimately re-adjust signaling and functional 
deficits (Manji and Duman, 2001). 
Although a comprehensive understanding of the genes and mechanisms 
underlying these transcriptional changes remains unclear, the recently formulated 
neurotrophic hypothesis considers the effects of antidepressant treatment via plasticity 
induced by altered expression of critical growth factors.  The neurotrophic hypothesis, 
complementary to the monoaminergic hypothesis, proposes drug action specifically 
through molecular stimulation of neuronal cell growth and stability (Duman et al., 1997, 
Altar, 1999).  Indeed, chronic antidepressant treatment has been reported to ameliorate 
depression-associated deficits in glial and neuronal densities in addition to attenuating 
decreases in neuronal arboring (Manji et al., 2001, Manji and Duman, 2001, Duman and 
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Monteggia, 2006).  Compared to untreated, depressed control brain, antidepressant 
treatment was found to stimulate cell growth and resiliency in limbic and cortical brain 
regions (Manji and Duman, 2001) as well as attenuating, or even reversing atrophy of 
hippocampal cells in depressed patients (Sheline et al., 2003, Vermetten et al., 2003). 
With the neurotrophic hypothesis in mind, examination of the cellular and 
molecular effects associated with the pathophysiology and treatment of depression has 
included a strong focus on brain derived neurotrophic factor (BDNF).  Expressed 
abundantly in the developing and adult brain in midbrain, amygdala, hypothalamus, 
cerebral cortex and hippocampus, this neurotrophin and its receptor, TrkB (tropomyosin-
related kinase), are highly important for the maturation, function and survival of neurons 
(Huntley et al., 1992, Masana et al., 1993, Lindsay et al., 1994, Lindvall and Odin, 1994, 
Nibuya et al., 1995, Chan et al., 2006).  In addition to decreased BDNF plasma levels 
noted in depressed patients (Karege et al., 2002), postmortem studies found elevated 
BDNF immunoreactivity in hippocampal subregions of depressed patients who were on 
antidepressant drugs at the time of death (Chen et al., 2001).  Moreover, recent reports 
have linked a non-conservative BDNF polymorphism (Val/Met66) to several forms of 
major depression (Hwang et al., 2006, Naoe et al., 2007).  
Despite these discoveries, the association of BDNF with depression remains 
inconsistent. Furthermore, given the heterogeneous nature of human mood disorders, 
clinical research becomes limiting.  Thus, more animal work is required in order to 
examine defined aspects of depression and associated treatment mechanisms. 
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Animal models of depression 
Considerable effort has been given to mirroring the effects of human depression 
in laboratory animal models. (Table 1-2) While rodent models include selectively bred, 
stress-sensitive subpopulations, these examples are limited (Henn and Vollmayr, 2005).  
Animal models of depression are based primarily on behavioral changes induced in wild-
type strains by environmental stimuli (stress).  These models have been approached by 
recreating particular symptoms of mood disorders in behavioral tests including those 
designed to address anxiety, despair and learned helplessness (Berton and Nestler, 2006).  
Moreover, the stress-induced models selected have a strong construct, or face validity, 
closely paralleling the human disorder. 
A classic example of a behavioral-despair model is the forced swim test 
(“Porsolt’s test”).  Developed 40 years ago, the forced swim test is based on an animal’s 
response to a stressful, yet inescapable situation – in this case, swimming in a container 
of water with no exit.  Comparison of the time spent swimming with the time spent 
immobile is used as a measure of depressive-like symptoms (Porsolt et al., 1977b).  The 
general template of this model is recapitulated in the tail-suspension test, and importantly, 
these behavioral models have excellent predictive validity for providing evidence on the 
efficacy of antidepressant drugs when applied in humans, particularly in the case of 
despair-based models and monoaminergic-based treatments (Berton and Nestler, 2006).  
Further work in animal models of depression has demonstrated that, analogous to 
clinical research, antidepressant treatment induces brain region-specific alterations in 
BDNF expression.  In rat hippocampus, mRNA levels of BDNF and TrkB were shown to 
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be increased by treatment with physical activity, ECT or several antidepressant drugs 
(Nibuya et al., 1995, Russo-Neustadt et al., 2000).  Direct midbrain-infusion of BDNF in 
rats resulted in antidepressant-like behavioral responses in the forced-swim test and in a 
learned helplessness model of depression (Siuciak et al., 1996).   
Interestingly, expression of BDNF in rat hippocampus following antidepressant 
treatment was shown to be dynamically regulated with time (Coppell et al., 2003), which 
may explain some of the variability seen in human postmortem studies.  Additionally, 
although only a single BDNF protein exists, work in rodent models has revealed that 
several BDNF transcript variants respond differentially to antidepressant treatment, 
depending on treatment type and duration (Timmusk et al., 1993, Russo-Neustadt et al., 
2000, Dias et al., 2003, Tsankova et al., 2006a, Yasuda et al., 2007).  Furthermore, mouse 
models of BDNF and TrkB deficiency have underscored the potential role for this 
neurotrophin in the development and etiology of depression (Lyons et al., 1999, 
MacQueen et al., 2001, Rios et al., 2001, Monteggia et al., 2004, Chan et al., 2006), as 
well as the transcription factor cAMP response element-binding protein (CREB, (Nibuya 
et al., 1996).  Providing support to the neurotrophic hypothesis, these neurotrophins, 
CREB and its downstream targets (BDNF included) interact through a number of 
molecular cascades that have been linked to the pathogenesis and treatment of mood 
disorders.  
Cell-surface receptor stimulation by monoamines and growth factors activate 
intracellular cascades including the cAMP second messenger system, the mitogen 
activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) pathway, the 
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phosphoinositol cycyle, and the GSK-3 (glycogen synthase kinase-3) signaling pathway 
(reviewed in (Tanis and Duman, 2007).  In addition to myriad other effects, each of these 
pathways can be traced to the downstream-regulation of CREB activity.  Thus, a putative 
mechanistic framework takes shape incorporating antidepressant treatment with receptor 
signaling, diverse intracellular cascades, and ultimately, regulation of transcription and 
gene expression.  
 
Stimulant drug abuse: Overview 
Addiction to stimulant drugs represents a significant public health issue in terms 
of medical, psychological and social problems (de Lima et al., 2002).  In addition to 
effects on the primary user, impacts of drug abuse include increased infection of HIV and 
hepatitis as well as detrimental outcomes of prenatal drug-exposure (Volkow, 2004).  The 
following section, although focusing on cocaine, provides a general mechanistic 
overview of stimulant addiction as well as underscoring the fact that effective treatment 
for stimulant abuse does not exist.   
 
Brain regions affected and molecular effects of stimulant abuse: 
‘Psychostimulant’ refers to drugs that produce a spectrum of stimulatory effects in 
humans.  These drugs include cocaine, amphetamine, methamphetamine and 
methylphenidate and can be used therapeutically for ADHD or can be potently addictive 
(Musto, 1992, Das, 1993, Gonzalez Castro et al., 2000).  Each stimulant affects the brain 
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uniquely, yet have been consistently shown to converge on the reward circuitry of the 
limbic system (Fig.1-1)(Nestler, 2005).  
Regulated primarily by dopamine, the mesolimbic reward pathway is believed 
responsible for the acute reinforcing effects of drugs of abuse (Kreek et al., 2002, 
Heidbreder and Hagan, 2005).  Specifically, acute administration of any drug of abuse 
functions to activate dopaminergic neurons projecting from the ventral tegmental area 
(VTA) to the nucleus accumbens (NAc) and other targets in the forebrain (Fig. 1-1).  
Indeed, in the case of cocaine, inhibition of presynaptic transporters of dopamine (DA), 
serotonin and norepinephrine increases synaptic levels of each of these neurotransmitters 
(Kreek et al., 2002).  However, given the role of dopamine in the brain’s reward pathway, 
a major focus of cocaine addiction research has been in regard to this monoamine.  
Decades of research have consistently implicated dopaminergic signaling in the 
mechanisms underlying cocaine addiction.  The link between dopamine and reward was 
first established, in part, by reports showing that psychostimulant self-administration was 
reduced with dopamine receptor blockade (Gunne et al., 1972, Wilson and Schuster, 
1972, Yokel and Wise, 1976, De Wit and Wise, 1977).  Further supportive evidence 
came from studies showing that chemical lesions of the dopmainergic pathway attenuated 
cocaine self-administration (Roberts et al., 1977, Roberts et al., 1980, Roberts and Koob, 
1982).  Extensive structure-function studies of the transporters targeted by cocaine led to 
the dopamine hypothesis named for the high correlation of dopamine transporter (DAT)-
blockade studies proposing that cocaine’s rewarding effects were a result of DAT-
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inhibition-induced increases of synaptic dopamine (Ritz et al., 1988, Spealman et al., 
1989).  
Indeed, behavioral analysis of DAT knockout mice showed a lack of cocaine-
induced locomotor response in comparison to wild type controls (Giros et al., 1996, Sora 
et al., 1998, Sora et al., 2001).  However, in the conditioned place preference (CPP) test, 
where preference for a drug-associated environment is measured, cocaine-treated DAT 
knockout mice performed no differently that wildtype control mice (Sora et al., 1998).  
Furthermore, DAT knockout mice showed no attenuation of cocaine self-administration 
(Rocha et al., 1998a).  Thus, these studies show that DAT knockout mice recapitulate 
some, but not all of the behavioral effects of cocaine.  More recently, self-administration 
studies in mice lacking one or more types of transporters for dopamine, serotonin and 
norepinephirne (DAT, SERT, NET) have shown dynamic response to cocaine 
reinforcement (Rocha et al., 1998b, Xu et al., 2000, Sora et al., 2001).  Specifically, 
although single knockouts of DAT (Rocha et al., 1998b), SERT (Sora et al., 1998), or 
NET (Xu et al., 2000) showed no change in cocaine-related reward, DAT/SERT double 
knockout eliminated cocaine reward (Sora et al., 2001), while SERT/NET double 
knockout enhanced cocaine reward (Hall et al., 2002).  These studies provide evidence 
that multiple neurotransmitter systems are likely involved in the regulation of cocaine 
abuse.  However, additional factors have been implicated in the mechanims that mediate 
cocaine’s effects, in particular, regulation of transcription and gene expression.    
The association of changes in transcription and gene expression with 
administration of addictive substances is not a new idea (reviewed by (Mackler and 
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Eberwine, 1991).  Reports have shown in vivo, that acute administration of cocaine 
induces increased mRNA levels of early response genes, including c-fos (Hope et al., 
1992).  Work on the transcription factor splice variant, ΔfosB, has demonstrated that 
chronic treatment with any drug of abuse, including cocaine, induces accumulation of the 
uniquely stable ΔfosB protein in the NAc, though the mechanisms associated with this 
accumulation remain unclear (Nestler et al., 2001, McClung et al., 2004).  Chronic 
cocaine administration also induces dynamic gene expression changes in tyrosine 
hydroxylase (TH), the rate-limiting enzyme in catecholamine biosynthesis (Nestler, 1992, 
Lu et al., 2003), however these responsive changes in TH may not be surprising given 
that cocaine is known to block the reuptake transporters of dopamine and norepinephrine.  
Finally, neurotrophins, including BDNF have been implicated in the development of 
psychostimulant abuse (Horger et al., 1999, Pierce et al., 1999, Grimm et al., 2003, Lu et 
al., 2004, Filip et al., 2006, Corominas et al., 2007).  These various biochemical changes 
can be viewed as drug-induced neural plasticity. 
 
Treatment of cocaine abuse: 
Efforts to treat cocaine abuse have focused on the dopaminergic system, which 
via a plasticity-related mechanism becomes dysfunctional following chronic cocaine 
abuse.  Extended cocaine use decreases basal DA signaling, however cocaine or 
associated environmental cues sensitize DA receptors.  These complex effects are thought 
to contribute to the symptoms of depression and craving experienced during cocaine 
withdrawal (de Lima et al., 2002).  Compensation for these monoaminergic deficits has 
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been the primary basis for addiction therapy, which utilizes antidepressants and D1-
receptor agonists.   
First examined in rodent models, single-drug behavioral testing revealed that D1-
agoinst treatment, as with cocaine treatment, stimulates locomotor activity (Le Moine et 
al., 1997, Schindler and Carmona, 2002, Nergardh et al., 2005) (see also Table 1-2).  
However, evidence that co-administration of D1-agonists with cocaine caused decreases 
in cocaine use prompted clinical attention.  Specifically, it was shown that combined 
treatment with D1-agonists and cocaine decreased cocaine self-administration in non-
human primates (Katz and Witkin, 1992, Caine et al., 2000) and rodents (Caine et al., 
1999, Self et al., 2000, Chausmer and Katz, 2002) as well as decreasing the subjective 
effects of cocaine-use in humans (Haney et al., 1999).  However, the efficacies of these 
treatments, in addition to other treatment options, remain dramatically limited. This was 
highlighted by a recent review of 45 clinical trials of cocaine abuse therapy; many of the 
treatments utilized antidepressants or dopamine agonists, but unfortunately, the overall 
conclusion was that there was no significant effect of any addiction-reducing therapy (de 
Lima et al., 2002).   
Indeed, more recent attempts to treat cocaine dependence have used the 
antiepileptic and mood stabilizer, sodium valproate (SV).  An open-label trial of 
correlated increased valproate plasma levels with cocaine abstinance (Halikas et al., 
2001).  This effect was supported by mouse behavioral experiments showing that 
valproate treatment decreases cocaine-induced locomotor activity (Herzog et al., 2007).  
The mechanisms that underlie these very preliminary findings may include known effects 
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of SV, including inhibition of protein kinase C, activation of mitogen-activated protein 
kinases and increased B-cell lymphoma 2-family (Bcl-2)-mediated cell survival as 
reviewed in (Einat and Manji, 2006), as well as induction of neuronal differentiation 
inhibition of histone deacetylation (Hsieh et al., 2004).  As outlined in the next section, 
chromatin remodeling, including histone acetylation, has a dynamic role in the regulation 
of gene transcription and thus, is of particular interest in further determination of the 
molecular actions and future treatment paradigms of stimulant abuse. 
 
Histone Modification, Chromatin Structure and Function: Overview 
Within each cell, gene expression is under exquisite control as evidenced by the 
myriad cell types within the body, whose unique phenotypes -established during 
development- result from specific programs of gene expression.  Additionally, cells are 
able to make adjustments to transcription on a more acute time-scale in response to 
environmental stimuli.  Both the establishment of cell-specific gene expression programs 
during development and more acute, minute-to-minute alterations are regulated by 
epigenetic changes: chemical modification of DNA and histone proteins.  This section 
will provide a basic overview of histone modification, chromatin structure and the impact 
these have on transcriptional regulation as well as therapeutic implications for chromatin-
modifying drugs in depression and stimulant abuse. 
The most basic organizational unit of DNA is the nucleosome: stretches of 147 
base pairs (bp) of DNA wrapped 1.7 times around an octameric core of histone proteins 
comprised of two histone (H) H2A-H2B dimers and an H3-H4 heterotetramer.  Between 
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each nucleosome, short lengths of DNA (10-60bp) link the nucleosomes together forming 
the familiar 10nm chromatin fiber, which appears as ‘beads on a string’ (reviewed in 
(Peterson and Laniel, 2004).  Further compaction of chromatin to the 30nm fiber is 
facilitated by linker histones, and this 30nm fiber is condensed still more by other 
proteins, resulting in higher-order structures with architecture that remains unclear 
(Peterson and Laniel, 2004, Wang et al., 2007b).  Importantly, while DNA compaction 
facilitates its efficient packaging in the nucleus, vital cellular functions require 
mechanisms that de-condense chromatin, making DNA accessible for processes including 
DNA replication (in dividing cells) and transcription.   
As many factors work in concert to condense (close) chromatin, there are several 
mechanisms that reverse this process, though in a manner of surprising specificity.  One 
such mechanism centers around the core histones – particularly, their individual 15-38bp 
N-terminal tails.   The N-terminal tails of core histones, in addition to the C-terminal tail 
of H2A, extend outward from their central globular domain and critically impact the 
formation of higher-order chromatin structure (Luger et al., 1997, Peterson and Laniel, 
2004).  This relationship was evidenced from studies showing that, in vitro, core histones 
harboring N-terminal tail deletions could not condense beyond the 10nm chromatin fiber 
(Hansen, 2002, Peterson and Laniel, 2004).   
The histone tails are subject to a wide variety of covalent, residue specific 
modifications, including methylation, phosphorylation and acetylation.  These post-
translational modifications further impact the role of histone tails in chromatin folding as 
illustrated by a study showing that increased histone tail acetylation resulted in deficient 
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formation of 30nm chromatin fibers (Tse et al., 1998).  Highly condensed chromatin is 
thought to result, at least in part, from tail-mediated histone-histone interactions as well 
as tail-mediated binding of non-histone effector proteins.  It should be noted that, 
although histone modifications do indeed alter amino acid charge and are important for 
higher-order chromatin structure and function (Hansen, 2002, Kouzarides, 2007), in 
contrast to previous models, these charge alterations likely have little impact on the 
wrapping of DNA around the core nucleosome.  Deficiencies in 30nm chromatin fiber 
compaction via histone tail acetylation was recently refined to a single modification; 
acetylation of histone H4-Lys16 (Shogren-Knaak et al., 2006).  This work also illustrated 
that H4-K16 acetylation prevented the interaction of an effector protein with the 
chromatin fiber (Shogren-Knaak et al., 2006).              
While this novel example suggests a critical regulatory mechanism for the single-
residue modification, H4-K16ac, in the regulation of chromatin structure, a hypothesis for 
a ‘histone code’ was developed based on the observation that cellular functions appeared 
to be associated with specific combinations of histone tail modifications (Jenuwein and 
Allis, 2001, Peterson and Laniel, 2004) and has since associated defined histone 
modification patterns with processes, including transcriptional activation, repression and 
ATP-dependent chromatin remodeling.  However, the context in which the histone code 
is read can result in different cellular functions depending on cell type, non-histone 
‘effector’ proteins present, and the gene under examination (Peterson and Laniel, 2004). 
As such, the recognition of histone tail modifications or ‘reading’ of the histone 
code represents a highly important step in resultant chromatin structure and function.  
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Proteins containing small, histone-binding modules represent key players in the reading 
of the histone code.  Specifically, chromodomain-containing proteins can recognize 
methylated lysine residues and bromodomain-containing proteins result in specific 
binding to acetylated lysines.  Further binding specificity of a module with a particular 
histone modification can depend on the non-histone binding protein.  That 
Heterochromatin Protein 1 (HP1) and Polycomb proteins both contain chromodomains, 
yet selectively bind to dimethyl H3Lys9 and dimethyl H3Lys27, respectively, supports 
the view that combinations of residue modification act as part of a regulatory system to 
control these interactions (Wang et al., 2007a).   Other aspects in the regulation of 
histone-effector binding and activity include neighboring residues on the N-terminal tail 
as well as the distinct enzymatic action of the non-histone binding protein.  One such 
example is the protein General Control Nonderepressible 5, a member of the 
transcriptional activation complex and histone acetyl transferase.  This protein 
preferentially acetylations lysine residues 9 and 14 on the histone H3 N-terminal tail; 
sites of action distinct from the histone H4 lysines 4, 8, 12, and 16 targeted by the human 
Nucleosome Acetyltransferaes of H4 HAT complexes, (Peterson and Laniel, 2004). 
Importantly, a number of these small histone-binding module-containing proteins 
are present in ATP-dependent chromatin-remodeling enzyme complexes.  Chromatin 
remodeling is a process generally defined as nucleosomal structural changes including 
dissociation of DNA-histone contacts, translocation of the nucleosome along DNA, 
removal of histones from DNA, and exchange of histones for histone variants (Wang et 
al., 2007a).  Mammalian chromatin remodeling ATPases include the switching 
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defective/sucrose non-fermenting (SWI/SNF) enzymes, both of which contain C-terminal 
bromodomains (thus binding acetylated histone tails) and primarily promote accessibility 
for transcription factor binding by disorganizing and reorganizing nucleosomal 
positioning (Martens and Winston, 2003, Wang et al., 2007b).  However it is important to 
note that these enzymes have also been shown to recruit transcriptional repressors (Ooi et 
al., 2006).  These enzymes and other ATPases- function in concert with histone tail 
modifications and DNA methylation to alter the structure of the nucleosome by 
dissociation of the DNA-histone contacts (looping), translocation of the nucleosome 
along DNA (sliding) and removal and exchange of histones.  While histone modifications 
play a critical role in these processes, it is important to emphasize that chromatin 
remodeling requires ATP-dependent enzymatic activity to bring about such nucleosome 
structural changes (Wang et al., 2007b).  
 
Histone Acetylation 
The study of histone modification has focused on the acetylation of histone tails, 
particularly of histones H3 and H4.  This modification is controlled by the opposing 
action of two classes of enzymes: histone acetyltransferases (HATs) and histone 
deacetylases (HDACs).  Both HAT- and HDAC-families contain multiple members 
whose enzymatic targets include not only histones, but also transcription factors (Glozak 
et al., 2005).  Furthermore, some of the more than 20 HAT-family members, including 
p300/CBP (CREB Binding Protein), General Control Nonderepressible 5 (Gcn5), 
p300/CBP-associated factor (PCAF) and Steroid receptor coactivator-1 (SRC-1), act as 
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transcription factors themselves via interaction within the transcription activation 
complex (Peterson and Laniel, 2004, Black et al., 2006a).  Similarly, HDAC-family 
members have been shown to interact in transcriptional co-repressor complexes with 
proteins, including Methyl CpG binding protein 2 (MeCP2) and Mothers against 
decapentaplegic (Mad) (Nan et al., 1997, Sommer et al., 1997). 
Further, mutations of either HAT or HDAC family-associated proteins are 
sufficient to induce specific pathological outcomes.  For example, mutations localized to 
the CBP locus have been found in many patients with Rubinstein-Taybi Syndrome, a 
form of mental retardation (Petrij et al., 1995).  Additionally, Rett syndrome, an X-linked 
neuropsychiatric disorder, is highly correlated with a mutation in the MeCP2 gene (Amir 
et al., 1999, Akbarian, 2003).  Of note, CBP and MeCP2 each have multiple functions, 
only one of which is the regulation of histone acetylation.  However, these clinical 
associations underscore the critical roles individual chromatin modifying enzymes have 
in maintaining the plasticity of a cell and its genome.  
Indeed, the association between histone hyperacetylation (particularly H3 and H4) 
on nucleosomes surrounding promoter-region DNA of genes showing increased 
transcription is well established (Allfrey et al., 1968, Grunstein, 1990, Struhl, 1998, 
Brown et al., 2000).  Additionally, reports associating histone acetylation with the 
accessibility of DNA and binding of transcription factors (Lee et al., 1993, Vettese-
Dadey et al., 1996, Struhl, 1998) are suggestive of a direct transcriptional regulatory 
mechanism.   Nevertheless, while further work is required to elucidate the regulatory 
roles of dynamic histone acetylation changes at specific gene-promoter sequences, 
21 
research has been facilitated by application of pharmacological agents that inhibit HAT 
or HDAC.  
 
Histone Acetylation: Pharmacology 
Examination of in vitro and in vivo changes induced by altered histone acetylation 
has relied on several broad-acting histone deacetylase inhibitors (HDACi) including the 
short chain fatty acids, sodium butyrate (SB) and sodium valproate (SV), in addition to 
suberoylanilide hydroxamic acid (SAHA) and Trichostatin A (TSA).  Each of these 
compounds robustly disrupts the histone acetylation equilibrium set by HAT and HDAC 
enzymes.  While each HDACi has unique features, these well-known examples inhibit 
the majority of class I/II HDACs, underscoring their comprehensive action (Davie, 2003, 
Dokmanovic et al., 2007a).  Known HDAC family members, 18 to date, have been 
segregated into 4 classes based on homology with yeast proteins.  A recent review 
summarizes: Class I (HDAC 1-3, 8) are primarily nuclear and interact with DNA through 
multi-protein complexes; Class II (HDAC 4-7, 9 and 10) contain motifs for nuclear and 
cytoplasmic localization, and can thus shuttle between the two; Class III HDACs are 
NAD-dependent homologs of the yeast protein, Sir2; and the recently created, Class IV 
HDACs (HDAC 11) have properties of both Class I and II HDACs (Dokmanovic et al., 
2007b).   
When introduced to mammalian cells in vitro, broad-acting HDAC inhibitors 
robustly increase acetylation levels of H2A, H2B, H3 and H4 (reviewed in (Marks et al., 
2001).  Interestingly, recent microarray profiling of HDACi-treated mammalian cells 
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revealed that gene expression changes were only detectable in a small fraction of genes 
analyzed; whereas 3% of affected genes showed increased transcription, 4% showed a 
decrease in response to HDACi treatment (Mariadason et al., 2000, Nusinzon and 
Horvath, 2005).  Moreover, treatment of adult progenitor cells with valproate, in vitro, 
has been shown to induce neuronal differentiation (Hsieh et al., 2004).  Together, these 
data illustrate that histone hyperacetylation induced by non-specific HDACi has 
transcriptional effects that are both limited and dynamic and may play a role in the 
mechanisms underlying neuronal plasticity.  
 
Histone Acetylation: Behavioral Effects 
 In vivo treatment with the class I/II HDACi, sodium butyrate, revealed further 
exciting evidence suggesting that HDACi are sufficient to induce not only chromatin 
modification and changes in gene expression, but also to dramatically alter an animal’s 
behavioral response.  At the outset of our studies in 2003, work by Ferrante and 
colleagues showed that extended SB administration improved neurological and motor 
deficits in a mouse model of Huntington’s disease.  Of note, SB readily crosses the 
blood-brain barrier and is a structural homolog to SV, a small molecule used in clinical 
treatment of epilepsy and as a mood stabilizer (Egorin et al., 1999, Amann et al., 2007).  
More recently, several publications have associated HDACi treatment in rodents 
with robust behavioral effects; enhancement of cocaine-induced reward (Kumar et al., 
2005), antidepressant-like effects in social defeat stress depression models (Tsankova et 
al., 2006a) (see also Table 1-2) and improved learning and memory (Fischer et al., 2007).  
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These behavioral results, summarized in the following table, underscore the pleiotropic 
effects of SB (and other HDACi) and its ability to induce diverse phenotypic response in 
animal models.   
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Study Class I/II HDACi treatment Behavioral Response 
Kumar et al,  
Neuron 2005, v.48(2) 
Sodium Butyrate  2-fold increase in cocaine-
induced locomotor activity 
Tsankova et al,  
Nat Neurosci 2006, v.9(4) 
Sodium Butyrate 2-fold improvement in 
social defeat stress  
Fisher et al,  
Nature 2007, v.447(7141) 
Sodium Butyrate 1.5 / 2-fold improvement in 
associative/spatial learning 
Kumar et al,  
Neuron 2005, v.48(2) 
Trichostatin A  2-fold increase in cocaine-
induced place preference 
Table 1-1: HDACi-induced behavioral changes in mice.  
Model Main Feature 
Anxiety-based tests 
  -Light Dark Box 
  -Open Field Test 
The degree to which aniamls explores a particular environment  
(open space, brightly lit area, elevated area) is increased by  
anxiolytic drugs (e.g., benzodiazepines). 
 
Tail Suspension Test Antidepressants acutely increase the time an animal struggles when 
suspended by its tail; lack of struggling thought of represent a 
state of despair. 
 
Forced Swim Test Antidepressants acutely increase the time an animal struggles in a 
chamber of water; lack of struggling thought to represent a  
state of despair. 
Chronic mild stress 
 
Animals exposed repeatedly to several unpredictable stresses (cold, 
disruption of light-dark cycle, footshock, restraint, etc.) show 
reduced sucrose preference and sexual behavior; however, these 
endpoints have been difficult to replicate, particularly in mice. 
 
Social Stress 
 
Animals exposed to various types of social stress (proximity to 
dominant males, odors of natural predators) show behavioral 
abnormalities; however, such abnormalities have been difficult to 
replicate, particularly in mice. 
 
Locomotor Activity Measure animal’s response to novel homecage environment 
Reward-based tests 
 -Cocaine CPP 
Animals show highly reproducible responses to drugs of abuse (or 
to natural rewards such as food or sex) in classical conditioning 
and operant conditioning assays. 
 
 
Table 1-2: Selected behavioral models used in depression and addiction research 
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Finally, from these collective background data, I sought to determine the 
biochemical and behavioral effects of a chromatin-modifying drug in the context of 
animal models of depression and stimulant abuse.  Specifically, I hypothesized that 
systemic treatment with sodium butyrate (SB) as single drug, or in combination with the 
SSRI, fluoxetine, would improve behavioral response in a mouse model of depression.  
Further, I proposed that this behavioral response would be observed at doses of SB that 
increase bulk histone acetylation levels, and would associate with changes in BDNF 
transcription in the hippocampus and frontal cortex (Chapter II).   
Additionally, given the emerging evidence for an impact of HDAC function on 
the stimulant and rewarding effects of cocaine, I hypothesized that sensitization of the 
dopaminergic system by combined treatment of SB with the dopamine D1-receptor 
agonist, SKF82958 (SKF), would enhance an animal’s behavioral response to subsequent 
cocaine challenge.  I also proposed that SB+SKF combination treatment would be 
associated with changes in transcription of tyrosine hydroxylase and BDNF in addition to 
chromatin modification changes in the promoter regions of these genes (Chapter III).  
This hypothesis was expanded in a rodent neuroimaging study to examine the proposal 
that cotreatment of cocaine with the HDACi, sodium butyrate, would result in increased 
cocaine-related brain metabolic activation, whereas cotreatment of cocaine with the 
HATi, curcumin, would result in attenuated cocaine-related brain metabolic response 
(Chapter IV).  Considering the preliminary evidence of HDACi-mediated behavioral 
changes in the context of both depression- and stimulant-drug abuse mechanisms, it was 
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interesting to speculate as to the impact of this experimental pharmacology.  The details 
of our findings are outlined below. 
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Figure 1-1:  Simplified neurotransmitter pathways for serotonin (blue lines) and 
dopamine (red lines*) in the rodent brain.  These basic circuits are highlighted given the 
importance of serotonin signaling in depression (see Chapter II) as well as dopaminergic 
signaling in stimulant drug reward and addiction (see Chapters III/IV).  It should be 
appreciated that serotonergic neurons project from the dorsal raphe to extensive forebrain 
targets that include the hippocampus and frontal cortex.  Similarly, dopaminergic neurons 
project in four major pathways to a number of regions in the forebrain: mesolimbic, 
mesocortical, nigro-striatal, and tuberoinfundibular (*hypothalamus to median eminence, 
green). 
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Figure 1-2:  Histone tail modification.  Modification of histone N-terminal tails, 
including acetylation (Ac) of lysine residues (K), is involved in the dynamic recruitment 
of transcriptional regulatory machinery.  Histone acetylation is regulated by two families 
of enzymes, histone deacetylases (HDAC) and histone acetyltransferases (HAT).  A 
major subset of HDACs (most class I and II HDACs) are subject to inhibition by the 
short chain-fatty acid, sodium butyrate (see Chapters II-IV).  Similarly, HAT function 
can be significantly inhibited by the drug curcumin (see Chapter IV).  Inhibition of either 
enzyme family is sufficient to dynamically alter general levels of histone acetylation.   
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CHAPTER II:   
Antidepressant-Like Effects of the Histone Deacetylase Inhibitor,  
Sodium Butyrate, in the Mouse 
 The work presented in this chapter is reproduced from a study by Schroeder et al., 
published in Biological Psychiatry (Schroeder et al., 2007) with minor changes in style 
and text.    
This work was conducted under the direction of Dr. Schahram Akbarian, and it is with 
gratitude to him and the other authors that I reproduce these data for the purposes of this 
dissertation.  My contributions to this work consisted of conducting all animal and 
biochemical experiments.  Cong Lily Lin contributed in scoring some of the behavioral 
tests as well as in executing a fraction of the western blotting and quantitative real-time 
PCR experiments.  Dr. Wim Crusio led design of the behavioral test battery and assisted 
in statistical analysis.  The manuscript was primarily prepared by Dr. Akbarian, while I 
contributed to the Results, Materials and Methods, figures and legends, and provided 
feedback on other sections. 
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 Abstract 
Background: Chromatin remodeling, including changes in histone acetylation, may play a 
role in the pathophysiology and treatment of depression. We investigated whether the 
histone deacetylase inhibitor, sodium butyrate (SB), administered as single drug or in 
combination with the SSRI, fluoxetine, exerts antidepressant-like effects in mice.  
Methods: Mice (C57BL/6J) received injections of SB, fluoxetine, or a combination of 
both drugs either acutely or chronically for a period of 28 days, and were subjected to a 
battery of tests to measure anxiety and behavioral despair. Histone acetylation, and 
expression of brain-derived neurotrophic factor, BDNF, was monitored in hippocampus 
and frontal cortex. 
Results: Co-treatment with SB and fluoxetine resulted in a significant, 20-40% decrease 
in immobility scores in the tail suspension test (TST), a measure for behavioral despair, 
both acutely and chronically. In contrast, decreased immobility after single drug regimens 
were limited either to the acute (fluoxetine) or chronic (SB) paradigm. Systemic injection 
of SB induced short-lasting histone hyperacetylation in hippocampus and frontal cortex.  
Among the four treatment paradigms that resulted in improved immobility scores in the 
TST, three were associated with a transient, at least 50% increase in BDNF transcript in 
frontal cortex, while changes in hippocampus were less consistent.  
Conclusions: The histone deacetylase inhibitor, SB, exerts antidepressant-like effects in 
the mouse. The therapeutic benefits and molecular actions of histone modifying drugs, 
including co-treatment with SSRIs and other newer generation antidepressants, warrant 
further exploration in experimental models. 
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Introduction 
Depressive disorders are among the most prevalent causes of illness-induced disability 
world wide (Murray and Lopez, 1997).  Notably, to date, all drugs approved as 
antidepressant medications are either inhibitors of monoamine transporters or monoamine 
oxidase (Cryan and Mombereau, 2004, Berton and Nestler, 2006) and take 6 – 8 weeks to 
exert their effects (Wong and Licinio, 2004). Still, treatment-resistant depression, which 
typically refers to inadequate response to at least one antidepressant trial of adequate 
doses and duration, affects up to 50%– 60% of patients (Fava, 2003). Given this 
background, there is a pressing need to develop conceptually novel treatments to obtain a 
therapeutic response in a higher proportion of patients. Importantly, exposure to 
antidepressant drugs and other treatments, including electroconvulsive seizures, alters 
gene expression patterns in corticolimbic circuitry, including frontal cortex and 
hippocampus (Manji et al., 1999, Coyle and Duman, 2003, Yamada et al., 2005).  Given 
that covalent histone modifications, including acetylation, play a key role for chromatin 
function and transcriptional regulation (Verdone et al., 2005), it is likely that differential 
regulation of histone acetylation contributes to these treatment-induced changes in gene 
expression. Indeed, in rodents, alterations in hippocampal gene expression in response to 
controlled seizures are associated with highly dynamic changes in histone acetylation in 
chromatin surrounding the promoter sequences of genes regulating transcription and 
neurotrophin signaling (Huang et al., 2002, Tsankova et al., 2004). Furthermore, a recent 
study showed that deacetylation of hippocampal histones blocks the ability of the 
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tricyclic antidepressant imipramine to reverse depression-like behavior in mice exposed 
to chronic psychosocial stress (Tsankova et al., 2006b). 
On the basis of these recent findings, the aim of this preclinical study was to further 
explore the antidepressant potential of drug-induced changes in histone acetylation. 
Specifically, for anxiety and behavioral despair in mouse models, I tested the 
antidepressant potential of sodium butyrate (SB), a prototype member of an emerging 
class of drugs, histone deacetylase inhibitors (HDACi) (Davie, 2003).   I hypothesized 
that systemic treatment with SB as single drug, or in combination with the SSRI, 
fluoxetine, would improve behavioral response in a mouse model of depression.  Further, 
I proposed that this behavioral response would be observed at doses of SB that increase 
bulk histone acetylation levels, and would associate with changes in BDNF transcription 
in the hippocampus and frontal cortex, two brain regions previously implicated in 
depression and treatment-associated changes in transcription.  Both in acute and chronic 
paradigms, I compared the antidepressant-like effects of SB with those of the selective 
serotonin reuptake inhibitor (SSRI) fluoxetine or a combination of both drugs.  The 
purpose of this dual drug-treatment design was test if SB treatment in combination with 
the clinical antidepressant, fluoxetine, would result in a greater therapeutic response 
compared to single drug treatment – an established treatment strategy (Zisook et al., 
2006).  I report, for the first time, that chronic treatment with SB, given as single drug or 
in combination with fluoxetine, is superior to single drug fluoxetine in improving 
behavioral despair. When injected systemically, SB induced a short-lasting, transient 
acetylation of histones in frontal cortex and hippocampus, in conjunction with dynamic 
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changes in expression of the brain-derived neurotrophic factor (BDNF), a model gene 
frequently implicated in behavioral and pharmacological models for depression (Duman, 
2004b). These novel findings warrant further investigations into the antidepressant 
potential of HDACi or SSRI and HDACi dual drug regimens. 
Materials and Methods 
Animals 
All experiments were conducted with adult male and female C57BL/6J inbred 
mice (age 9–22 weeks). Animals were housed in groups of 2–4/cage with food and water 
ad libitum. Animals were purchased directly from the Jackson Laboratory (Bar Harbor, 
Maine), housed under 12-hour light/dark cycle, and allowed to acclimate to new housing 
for at least 5–7 days before experimental manipulation. All experimental procedures were 
approved by the Institutional Animal Care and Use Committee of the University of 
Massachusetts. 
Drugs 
For all molecular and behavioral assays, data from drug-treated animals were compared 
with saline-treated cage-mate control subjects of the same gender. The following 
treatments were included in this study: 1) high-dose SB (1.2 g/kg); 2) low-dose SB (.2 
g/kg); 3) fluoxetine (10 mg/kg) with or without SB (.6 mg/kg). Control animals were 
treated with saline injections. Treatments were administered as acute, single dose (IP), or 
chronically, by IP injections once daily for 27–28 days (Figure 2-1). Drugs were 
dissolved in saline as vehicle; SB, or N-butyric acid sodium salt (Sigma-Aldrich, St 
Louis, Missouri) and fluoxetine hydrochloric acid (Mallinckrodt, Hazelwood, Missouri) 
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and were prepared fresh each day. For this study, SB was chosen for its effects on histone 
acetylation and fluoxetine was chosen as a prototype SSRI. To examine whether 
fluoxetine per se affects histone acetylation, I measured hippocampal H3 acetylation 30 
min and 2 hours after acute fluoxetine treatment.  H3 acetylation, selected as a well 
characterized, representative histone modification, revealed that in both groups, 
differences to saline-treated control subjects were 5% and not significant (data not 
shown). 
Behavioral Testing 
All animals were brought to the testing room at least 30 min before the start of 
each behavioral test and remained in the same room throughout the test. Tests were 
conducted during the light cycle between 7:30 AM and 2:30 PM. Behavioral tests were 
conducted every other day with a day of rest between each test while drug treatment 
continued as previously mentioned. Depending on drug, dose, and test, 12–36 
animals/experiment were used, with a matched number of saline-treated control subjects. 
In the chronic paradigm, each behavioral test was conducted 23 hours after the previous 
drug injection. Tests were applied in the following sequence (Figure 2-1): 1) light-dark 
box (LD), 2) open field, 3) tail suspension (TST), and 4) forced swim test (FST). In the 
acute paradigm, only one test was applied, the TST, 30 min after the injections. 
LD Exploration. Mice were introduced to a box (15x15x23 cm) consisting of one 
brightly lit open chamber connected by a small hole (4.5 cm) to a darkened, enclosed 
second chamber. Mice were placed into the lit compartment, and the time to the first 
transition, number of transitions between chambers, and time spent in each chamber were 
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manually recorded for 5 min after the first transition, with a 10-min maximum time 
(Crawley, 1999). 
Open Field Exploration. Animals were placed in a 108x49x49 cm open field 
constructed of black Plexiglas with a transparent front pane and an object mounted on the 
rear wall during a 30-min test session. Spontaneous behavior was recorded with a video 
tracking system (Ethovision, Noldus, Wageningen, The Netherlands). The following 
variables were measured: 1) average speed and 2) time spent in field’s central region or 
perimeter (thigmotaxis zone). 
TST.  Mice were suspended by securing a paper clip to the tail by wrapping 
adhesive tape around the tail, .75 cm from the tip; the clip then hung from a mounted 
hook 50 cm from the tabletop. Tail climbing was observed in only 3 of 209 animals, and 
data of these mice were removed from this test. The time to the first freeze (latency) and 
time spent immobile during a 6-min testing period were recorded in real time or by 
treatment-blind review of videotaped testing. No difference was found between real-time 
ratings and videotape-based ratings. 
FST. Mice were placed into a 4-L Pyrex beaker (13 cm diameter, 24 cm height) 
filled with 22°C water, 17 cm deep.  Latency to first freeze and time spent immobile 
during a 6-min testing period were measured. Immobility was defined according to 
criteria described (Schramm et al., 2001). In addition, data were analyzed for the last 4 
min of the test separately. As in the 6-min analysis, no significant differences between 
treatment and control groups were found (data not shown). 
Biochemical Analysis 
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Tissue Extraction. Mice were killed by cervical dislocation/ decapitation and 
whole brain was removed and processed immediately or snap-frozen on dry ice. 
Hippocampus was dissected bilaterally from coronal slices positioned between Bregma -
1.46 mm and -2.92 mm. Frontal cortex, which is defined here as the anterior cingulate 
cortex, or areas CG1 and CG2 of Paxinos and Franklin (Paxinos and Franklin, 2001b) 
and immediate surroundings were collected from Bregma 1.34 mm to .02 mm. To 
compare sodium butyrate-induced histone acetylation in central nervous system (CNS) 
with tissue not affected by the blood-brain barrier, liver samples were collected from the 
same animals and processed in parallel to CNS tissue samples. 
Western Blotting. Hippocampal and liver tissue were homogenized in Laemmli 
buffer, then incubated at 37°C for 10 min and centrifuged at 13,500 g at 4°C; the 
supernatant was denatured at 95°C for 5 min, then electrophoresed on a 10%–20% linear 
gradient Tris-HCl gel (Bio-Rad, Hercules, California) and transferred to polyvinylidene 
difluoride (PVDF) membrane (.2  m pore size; Bio-Rad). Immunostainings were 
performed with anti acetyl-histone H3 antibody (Upstate, #06-599; Lake Placid, New 
York) and, for loading control, anti-histone H4 antibody (Upstate, #07-108). 
Immunoreactivity was detected with peroxidase-conjugated secondary antibody (donkey 
anti-rabbit IgG; Amersham, Piscataway, New Jersey) in conjunction with 
chemiluminesence-based film autoradiography (Super Signal West Dura Extend Reagent; 
Pierce, Rockford, Illinois). For quantification, Quantity One (Biorad) software was used. 
Real Time Reverse Transcription Polymerase Chain Reaction. From each 
animal, total hippocampal and frontal cortex RNA was extracted with the trizol-based 
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RNeasy Lipid Tissue mini kit (QIAGEN, Valencia, California). Amplification reactions 
were performed in triplicate, with the ABI PRISM 7500 Real Time polymerase chain 
reaction (PCR) System (Applied Biosystems, Foster City, California) in conjunction with 
the One-Step reverse transcription (RT)-PCR kit (Applied Biosystems), SYBR green as a 
reference dye, and the following cycling protocol: 48°C, 30 min; 95°C, 10 min; followed 
by 45 cycles of 95°C 15 sec, 60°C 1 min. The BDNF primers were designed to amplify a 
117–base pair (bp) fragment from the BDNF coding sequence within exon VIII (Liu et 
al., 2006). The BDNF primer sequences: forward, gcgcccatgaaagaagtaaa; reverse, 
tcgtcagacctctcgaacct. A 133-bp fragment from mouse 18S ribosomal RNA (rRNA) was 
amplified in parallel reactions for normalization. The 18S rRNA primer sequences: 
forward, catggccgttcttagttggt; reverse, gaacgccacttgtccctcta. Quantification and 
normalization procedures were previously described (Stadler et al., 2005). Negative 
control assays included: 1) water only template, 2) RNA extracts from Nestin-Cre 
/BDNF1lox/1lox conditional null mutant mice (Rios et al., 2006), and 3) RNA extracts 
(from wildtype mice) not treated with reverse-transcriptase. No detectable amplification 
product was found for assays 1 and 3. For melting and amplification curves, see 
Supplement 2-1. 
Enzyme-Linked ImmunoSorbent Assay. The BDNF Sandwich enzyme-linked 
immunosorbent assay (ELISA) kit (Chemicon, Temecula, California) was used to assay 
protein levels from whole hippocampus. The BDNF levels measured were approximately 
50–150 pg/mg tissue, which is consistent with previous studies (Branchi et al., 2006). 
Statistical Analysis.  For each treatment group, mean value and SE were calculated, and 
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intra-group outliers (maximum 1/group) were removed by Grubb’s test: .05 significance 
level. The remaining data were compared with one-way analysis of variance (ANOVA), 
and the Tukey-Kramer or Least-Significant Differences tests were used for post hoc 
comparisons. 
 
Results 
Systemic administration of sodium butyrate induces a transient increase in histone 
acetylation in brain and liver 
Butyrate inhibits the activity of most HDAC subtypes, except class II HDAC 6 
and HDAC10 and all class III HDACs (Davie, 2003). Previous studies showed that 
peripheral administration of SB upregulates overall levels of histone acetylation in brain 
chromatin, but dose-response and temporal course of this effect remain unclear (Ferrante 
et al., 2003, Dong et al., 2005). Therefore, we injected mice with 1.2 g/kg SB, a dose that 
ameliorates the neurological phenotype in a mouse model for Huntington’s disease 
(Ferrante et al., 2003) and then determined, by immunoblotting, levels of histone H3 
acetylation in brain and liver at various timepoints (5-120 min and 24hrs) post-injection. 
In liver, an organ not affected by the blood-brain barrier, a rapid, 35% increase in overall 
H3 acetylation was observed during the first 30 min after injection when compared to 
saline-treated animals [F30min(1,9) = 6.65, p<0.03] (Fig.2-2A). However, within 60 
minutes, H3 acetylation levels in liver returned to baseline, and were followed by a small 
but significant decrease that lasted for at least 24 hours when compared to saline treated 
animals [F24hrs(1,8) = 10.66, p<0.01] (Fig. 2-2A). Similarly, H3 acetylation levels in 
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hippocampus peaked within 30 minutes, and then returned to baseline within 1 hour after 
SB injection when compared to saline treated animals [F30min(6,34) = 1.15, p<0.03] (Fig. 
2-2B). These kinetics remained unchanged even after 3 weeks of daily treatments (data 
not shown) and are consistent with the minute-scale half-life of the drug in humans 
(Miller et al., 1987).  Furthermore, a SB dose of 0.4 g/kg or greater was required in order 
to induce a significant increase in levels of hippocampal H3 acetylation in comparison to 
saline-treated control animals [F0.4g/kg(1,8) = 6.63, p<0.03; F1.2g/kg(1,8) = 5.3, p<0.05] (Fig. 
2-2C). To confirm that SB-induced acetylation is not limited to H3, we measured H4 
acetylation in hippocampal extracts (Fig. 2-2D). There was a significant, 3-fold increase 
in hippocampal H4 acetylation 30 min after SB injection in comparison to saline-treated 
animals [F1.2g/kg (1,8) = 26.03, p < 0.001].  To confirm that SB-induced acetylation affects 
corticolimbic regions other than hippocampus, we measured levels of H3 acetylation in 
tissue extracts from frontal cortex (Fig. 2-2D). There was a significant, 1.6-fold increase 
in frontal H3 acetylation 30 min after SB injection when compared to saline-treated 
control mice [F1.2g/kg (1,18) = 8.95, p < 0.01]. 
Chronic administration of SB, given as daily injection for up to 28 days, was 
tolerated at low (0.2 g/kg), intermediate (0.6g/kg) and high (1.2 g/kg) doses, and no drug-
related changes in weight were observed during this treatment period (data not shown). 
These findings are consistent with previous reports which showed that mice tolerate daily 
SB doses of 1.2 – 1.5 g/kg without apparent signs of toxicity (Ferrante et al., 2003, Ying 
et al., 2005). In addition, we observed that mice injected with SB show, independent of 
dose, a brief period of hypoactivity within the first 5 minutes post injection, and resumed 
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normal activity levels within 30 minutes post injection (data not shown). This finding is 
consistent with earlier studies conducted in cats (Matsuzaki et al., 1964).  
 
Sodium butyrate exerts antidepressant-like effects in a behavioral despair paradigm 
To examine the antidepressant potential of SB, mice were treated for a period of 4 
weeks with daily injections of either high (1.2 g/kg) or low (0.2 g/kg) dose SB or saline 
as control, while subjected in the 4th week to a battery of four tests to measure anxiety-
related behavior (light-dark box and open field test) and behavioral despair (tail 
suspension and Porsolt’s forced-swim test). To rule out acute drug or injection procedure-
related effects, each behavioral test was conducted 23 hours after the preceding injection. 
Significant treatment effects in the behavioral despair paradigms were found only in the 
group of animals treated with high dose SB when compared to their saline-treated control 
cohort (Fig. 2-3A). In the tail suspension test (TST), high dose SB animals showed a 25% 
increase in latency to the first freeze [F (1,64) = 9.49, p<0.003] and a 19% reduction in 
total freeze time, in comparison to saline-treated controls [F (1,64) = 6.59, p<0.013]. 
There were no significant differences between treatment groups and saline-treated control 
groups in the open field test (Fig. 2-3B) or forced swim test (data not shown). For the 
three parameters measured in the light-dark box experiment, the latency to the first cross 
into the dark compartment was differentially affected by high and low dose SB in 
comparison to respective saline-treated control groups [FSB-H(1,65) = 4.408, p<0.04; FSB-
L(1,42) = 6.17, p<0.017] , while total crossings and total time spent in the dark were not 
significantly altered from saline-treated controls (Fig. 2-3C).  
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Polypharmacy, i.e. co-administration of two or more antidepressants, may result 
in a better therapeutic response, in comparison to single-drug regimens (Zisook et al., 
2006). Therefore, we wanted to find out if co-treatment of SB with fluoxetine is superior 
to monotherapy with that SSRI. Mice were treated for a period of 4 weeks with daily 
injections of (i) an intermediate (0.6 g/kg) SB dose plus 10 mg/kg of fluoxetine, (ii) 
fluoxetine alone 10 mg/kg, or (iii) saline, and then subjected to the same behavioral test 
pattern as described above. Animals receiving both drugs showed approximately a 20% 
increase in latency to first freeze and a 26% decrease in total freeze time, in comparison 
to saline-treated controls. These changes were significant [FSB+Fluox(2,64) = 4.61, 5.51, 
p<0.01, 0.004](Fig. 2-4A). In contrast, behavioral despair measures in animals receiving 
fluoxetine as single drug were not significantly changed from saline-treated controls (Fig. 
2-4A). Furthermore, there were no significant differences between drug- and saline-
treated animals in the light-dark box test (Fig. 2-4C) and forced swim test (data not 
shown). In the open field test, animals treated with fluoxetine, with or without SB, 
showed a significant, 20-22% significant increase in thigmotaxis [FFluox+/-SB(2,59) = 8.83; 
p<0.001, 0.005] (Fig. 2-4B).  
Next, we wanted to find out if a single dose of SB, fluoxetine, or a combination 
thereof alters behavioral despair in mice. For this acute experiment, the same doses were 
administered that improved TST performance in the chronic paradigm. Thus, mice 
received either (i) SB (1.2 g/kg), or (ii) SB (0.6 g/kg) in combination with fluoxetine (10 
mg/kg), or (iii) fluoxetine (10 mg/kg) as a single dose, or (iv) saline as control. All 
animals were subjected to the TST 30 min after drug injection. Animals receiving dual 
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treatment (SB/fluoxetine) showed the most robust changes in the acute paradigm, as 
evidenced by a 40% increase in latency to first freeze and a 34% decrease in total freeze 
time, in comparison to saline-treated animals (Fig. 2-5A).  These differences were 
significant [FSB+Fluox(2,33) = 5.53, 6.41, p<0.008, 0.012]. Furthermore, animals that 
received fluoxetine showed a similar improvement in total freeze time, but less robust 
changes in latency to first freeze (Fig. 2-5A). In contrast, after acute treatment with SB as 
single drug, animals showed an increase in total freeze time [F(1,18) = 8.81, p<0.008] 
(Fig. 2-5B).  
Finally, we wanted to find out if the context of four separate behavioral tests (Fig. 
2-1) was a factor in the significant improvement in TST performance after chronic SB 
treatment (Fig. 2-2A). Therefore, we repeated the chronic treatment paradigm for SB (1.2 
g/kg) and saline as control in a separate group of mice, which were subjected the to the 
TST without prior exposure to other behavioral tests. In this group of animals, SB- and 
saline-treated animals did not show significant differences in TST measures [latency to 
first freeze (sec) treatment, mean ± S.E.: SB, 117.3 ± 9.2; saline, 121.2 ± 7.3; total freeze 
time (sec): SB, 112.7 ± 14.3; saline, 93.0 ± 5.9]. 
 
Bdnf expression in hippocampus and frontal cortex 
Among the molecules considered relevant for the pharmacology of depression, 
brain-derived neurotrophic factor, BDNF, is by far the most studied (Tardito et al., 2006). 
While there is robust upregulation of BDNF in hippocampus after repeated 
electroconvulsive seizures (ECS) (Nibuya et al., 1995, Altar et al., 2003, Dias et al., 
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2003, Tsankova et al., 2004), expression changes after fluoxetine treatment were less 
consistent (reviewed in (Tardito et al., 2006). Furthermore, the ECS-mediated increase in 
BDNF expression is not limited to the hippocampus but includes other corticolimbic 
brain regions such as the frontal cortex (Isackson et al., 1991, Nibuya et al., 1995).  
To determine if the observed improvement in the TST scores are associated with 
changes in hippocampal or frontal BDNF expression, we measured levels of BDNF 
mRNA and protein at various time points (30 min, 120 min and 4-6 hrs) after drug 
injection (Table 2-1). As outlined above, there were 4 treatment conditions associated 
with improved immobility scores, i.e. an antidepressant-like behavioral response:  acute 
fluoxetine with or without SB, chronic SB with or without fluoxetine, and saline as 
control. Three of these four treatment groups (acute fluoxetine with or without SB and 
chronic SB with fluoxetine) showed a transient upregulation of BDNF mRNA levels of 
50% or more in the frontal cortex (Table 2-1).  In two treatment groups, these changes 
reached the level of significance in comparison to saline treated control cohorts: acute 
fluoxetine [FFluox (2,12) = 2.45, p<0.05] and chronic SB plus fluoxetine [FFluox+SB(2,13) = 
88.04, p<0.01] (Table 2-1).  
In contrast to these treatment-induced increases in frontal BDNF, changes in the 
hippocampus were less consistent. There was a significant, 30-40% reduction in 
hippocampal BDNF mRNA within the first 30 min after fluoxetine injection, given alone 
or in combination with SB, in the chronic paradigm [FFluox+/-SB(2,12) = 7.02, p<0.05, 0.01] 
(Table 2-1). Notably, when administered as single drug, SB had neither in the acute nor 
in the chronic treatment paradigm any significant effects on hippocampal or frontal 
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BDNF levels (Table 2-1). These data suggest that increased BDNF expression in frontal 
cortex may be one of the molecular mechanisms that could contribute to antidepressant-
like behavior after chronic co-treatment with SB plus fluoxetine, or after acute treatment 
with fluoxetine ± SB.  
 
Discussion 
We report that in mice, the HDACi sodium butyrate (SB), improves performance 
in a behavioral despair paradigm, the tail suspension test (TST). Notably, combined 
treatment with SB and the SSRI, fluoxetine, was superior to fluoxetine monotherapy both 
in the acute and chronic paradigm. In addition, mice that received SB as a single drug via 
daily injections over a period of 3 weeks showed a significant improvement in the TST, 
when applied within a battery of four tests designed to measure behavioral correlates of 
anxiety and despair. In contrast, chronic treatment with fluoxetine, when given as single 
drug, was ineffective in this setting. For the antidepressant actions of SB, doses 
sufficiently high to induce a global and transient hyperacetylation of frontal and 
hippocampal histones were required. Notably, three of four treatment paradigms resulting 
in an antidepressant-like behavioral response were associated with dynamic changes in 
BDNF transcript levels, including a transient, more than 50% increase in the frontal 
cortex.  
 
Limitations of this study 
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Our study had several limitations. First, the significant improvement in TST 
scores after chronic treatment with SB was observed in mice that were subjected to the 
TST after completing the light-dark box and open field tests. When mice were subjected 
to the TST without the preceding tests, SB-treated animals did not show significant 
differences to controls. It is possible that by subjecting mice to the additional tests, the 
sensitivity of the animals to the antidepressant-like effects of SB in the TST was 
increased. Of interest in this context is the observation of (Tsankova et al., 2006b) that 
the antidepressant imipramine induced hippocampal histone hyperacetylation only in 
mice previously subjected to chronic social defeat stress, but not in non-stressed animals.  
This is quite analogous to humans, in which antidepressant drugs are only effective in 
depressed individuals, not normal people.  In addition, other types of histone 
modifications, such as phosphorylation and methylation, may be required for 
antidepressant action (Tsankova et al., 2004, Tsankova et al., 2006b). Second, while in 
our study a significant drug response was observed in the TST, no changes were found in 
another test for behavioral despair, the forced swim test (FST), which was the 4th test 
applied in the chronic paradigm of the present study. This may, however, not be 
surprising given that C57BL/6J mice are less sensitive to fluoxetine in the FST, in 
comparison to other strains (Lucki et al., 2001). Third, comparatively high doses of SB 
were required to obtain antidepressant-like effects. This was not associated with apparent 
toxicity or side effects other than a brief period of sedation after injection, and has been 
used previously with success to treat chronic neurodegenerative disease in mice (Ferrante 
et al., 2003, Ying et al., 2005). Sedation after systemic SB injection was limited to the 
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first 30 min post injection, and therefore not a confound for the behavioral tests in the 
chronic paradigm, which were applied 23 hours after drug administration. However, the 
findings reported here should be viewed as preliminary, pending further investigations.  
 
Co-treatment with SB and fluoxetine is superior to single drug regimen both in the acute 
and chronic paradigm 
In most patients, the therapeutic effects of antidepressant drug treatment are not 
seen for weeks after initiation of treatment (Wong and Licinio, 2004). In mice, however, 
the efficacy of antidepressants in behavioral despair tests, including the TST and FST, are 
typically studied following an acute dose of drug (Porsolt et al., 1977a, Steru et al., 
1987). Importantly, for drugs interfering with monoamine transporters and oxidases, 
these acute tests have good or excellent predictive validity, which is defined as the ability 
to predict therapeutic (antidepressant) efficacy in human subjects. Therefore, an acute 
paradigm was included in the present study. However, the predictive validity of any 
mouse model for a non-monoamine-based antidepressant remains unclear. Currently, this 
question cannot be addressed because all drugs approved to treat depression are 
monoamine-based (Berton and Nestler, 2006). To reproduce the requirement for 
prolonged drug action in humans, we included, in addition to the single dose paradigm, a 
chronic treatment paradigm. Importantly, C57BL/6J mice, which is the inbred strain of 
the present study, exhibit decreased immobility in the TST both after acute and chronic 
treatment with the tricyclic antidepressant, amitriptyline (Caldarone et al., 2003). 
Therefore, the C57BL/6J inbred strain is suited to examine antidepressant candidate 
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drugs both in acute and chronic paradigms. Notably, in the present study, the only 
treatment that resulted in improved TST scores both acutely and chronically was the dual 
drug regimen of SB and fluoxetine. In contrast, antidepressant-like effects of fluoxetine 
monotherapy were limited to the acute setting, and, conversely, SB monotherapy was 
only effective when administered chronically. Based on these findings in mice, we 
hypothesize that combined administration of an SSRI, together with a class I/II HDACi, 
could be promising new approach in the pharmacotherapy of depression.  
 
HDACi show therapeutic effects in a range of neuropsychiatric disorders 
There is increasing evidence for a role of histone acetylation in the neurobiology and 
pharmacology of mood disorders (Zarate et al., 2006).  Notably, the anti-convulsant and 
mood-stabilizing sodium valproate (SV), which is structurally related to SB, upregulates 
histone acetylation in CNS neurons (Tremolizzo et al., 2002, Yildirim et al., 2003, Dong 
et al., 2005).  Strong mechanistic evidence for a role of histone modifications in 
depression was provided by a recent study in mice showing that hippocampal mRNA 
levels for the histone deacetylase, Hdac5, are downregulated after chronic treatment with 
the tricyclic antidepressant imipramine and furthermore, forced overexpression of Hdac5 
antagonizes imipramine’s antidepressant action (Tsankova et al., 2006b). Based on their 
homology to yeast HDACs, mammalian HDACs are commonly divided into three classes 
(HDAC I, II and III). Class I HDACs are homologues of the yeast Rpd3 gene and class II 
HDACs, including Hdac5, are related to yeast Hda1 (Marks et al., 2003, Thiagalingam et 
al., 2003). The class III HDACs, or “sirtuins”, are related to yeast Sir2; they are 
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functionally distinct from class I/II HDACs and regulated by NAD+/NADPH (North et 
al., 2005). Drugs that act as HDAC inhibitors appear to block either class I/II HDACs or 
the sirtuins, but not both (Grozinger and Schreiber, 2002).  
Intriguingly, there is increasing evidence that class I/II HDACi ameliorate 
neurological symptoms across a wide range of neuropsychiatric disease models, in 
addition to the antidepressant action reported here. For example, chronic 
neurodegeneration associated with Huntington’s disease, dentato-rubral-pallidoluysian 
atrophy (DRPLA) and other polyglutamine repeat disorders is slowed or halted in rodents 
treated daily with SB and other class I/II HDACi (Ferrante et al., 2003, Hockly et al., 
2003, Minamiyama et al., 2004, Gardian et al., 2005, Ying et al., 2005). Furthermore, 
neuroprotective actions of HDACi were also reported in animal models of amyotrophic 
lateral sclerosis, or motor neuron disease (Ryu et al., 2005), and Parkinson’s disease 
(Gardian et al., 2004). Finally, hippocampal learning and memory is improved after 
systemic treatment with class I/II HDACi (Alarcon et al., 2004, Korzus et al., 2004, 
Levenson et al., 2004). Given that SB and other class I/II HDACi interfere with the 
balance between acetylation and deacetylation not only of HDACs, but also transcription 
factors and other molecules (Davie, 2003), multiple molecular mechanisms may underlie 
these neuroprotective and neurotrophic drug effects. Among these, cAMP-response-
element binding protein (CREB)-mediated transcription is a likely candidate. First, in 
hippocampus, CREB appears to be a crucial mediator of antidepressant effects (Carlezon 
et al., 2005, Tardito et al., 2006). Second, decreased gene dosage or expression of an 
inhibitory mutant form of CREB-binding protein (CBP), a histone acetyltransferase and 
49 
co-activator of transcription, impairs hippocampal long-term potentiation (LTP) and 
memory (Alarcon et al., 2004, Korzus et al., 2004, Wood et al., 2005). Notably, these 
deficits are ameliorated by treatment with class I/II HDACi (Alarcon et al., 2004, Korzus 
et al., 2004). Notably, SB and several other of the above-mentioned class I/II HDACi are 
effective at comparatively high doses (g/kg); therefore it will be interesting to explore the 
neuroprotective and behavioral potential of newer, more potent compounds such as MS-
275 (Simonini et al., 2006).  
 
Three of four treatments associated with an antidepressant-like response are 
accompanied by a transient upregulation of BDNF expression in frontal cortex 
In this study, three of four treatment conditions associated with an antidepressant-
like response (acute fluoxetine with or without SB, and chronic SB plus fluoxetine) were 
accompanied by an upregulation of BDNF levels in cortico-limbic portions of mouse 
frontal cortex. This would suggest that increased BDNF supply in that brain region is 
important for treatment response. This hypothesis is in agreement with postmortem 
studies reporting decreased levels of frontal and hippocampal BDNF in depression and 
suicide victims (Dwivedi et al., 2003). Furthermore, electroconvulsive seizures induce 
expression of neurotrophic factors, including BDNF, in rodent frontal cortex (Isackson et 
al., 1991, Nibuya et al., 1995, Angelucci et al., 2002). Finally, cellular signaling 
pathways downstream of BDNF are dynamically modulated in frontal cortex after 
treatment with mood-stabilizers (Einat et al., 2003). 
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In contrast to the observed increase in frontal BDNF expression, changes in the 
hippocampus were somewhat less consistent across treatment groups. There was a 
transient decrease in hippocampal BDNF mRNA after chronic fluoxetine (with or 
without SB) treatment. Among the hippocampal genes regulated in the context of 
antidepressant treatment, the nerve growth factor, Bdnf, is the one which has been most 
intensely examined (Tardito et al., 2006). However, there are conflicting results with 
regard to hippocampal BDNF mRNA or protein levels after fluoxetine treatment:  Three 
studies found an increase (Nibuya et al., 1996, Coppell et al., 2003, De Foubert et al., 
2004) while a fourth study reported a decrease (Miro et al., 2002). In addition, three 
studies found no changes in BDNF transcript or protein levels (Altar et al., 2003, Dias et 
al., 2003, Vinet et al., 2004). Furthermore, it has been shown that CREB-deficient mutant 
mice lack antidepressant-induced changes in BDNF expression, but maintain normal drug 
responses in behavioral despair paradigms (Conti et al., 2002). It should be emphasized 
that our findings, and the above-mentioned studies, do not exclude the possibility that 
hippocampal Bdnf and other CREB-regulated genes play an important role for 
antidepressant-like drug action in rodents. First, serotonergic neurotransmission is altered 
in hippocampus and other brain regions of Bdnf-deficient mutant mice (Lyons et al., 
1999, Rios et al., 2006). Second, ablation of Bdnf in forebrain (including hippocampus) 
results in an attenuated behavioral response to antidepressant drug treatment (Monteggia 
et al., 2004). Third, central administration of BDNF improves behavioral despair in the 
rat (Hoshaw et al., 2005). Therefore, BDNF plays an essential role in at least some 
antidepressant paradigms. However, further studies will be necessary to determine 
51 
additional brain regions in which changes in BDNF levels are meaningful the context of 
antidepressant drug treatment. To this end, it should be mentioned that BDNF exerts 
differential effects on antidepressant-like behavior, depending on the brain region 
involved. For example, local BDNF infusion into the vicinity of the midbrain 
serotonergic raphe nuclei exerts an antidepressant-like effect (Siuciak et al., 1997), while 
BDNF applied pharmacologically to the dopaminergic ventral tegmental area (VTA) has 
a prodepressant-like effect (Eisch et al., 2003). Conversely, genetic ablation of Bdnf in 
the VTA area results in antidepressant-like behavior (Berton et al., 2006). 
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Conclusion and further directions 
There is increasing evidence that transcriptional changes, particularly of plasticity 
associated genes, are mediated by chromatin remodeling mechanisms including dynamic 
changes in covalent histone modifications (Tsankova et al., 2004, Tsankova et al., 2006b) 
or DNA methylation (Weaver et al., 2004, Weaver et al., 2005) and play an important 
role in the pathophysiology and treatment of depression. Here, I report, in support of part 
of my hypothesis, that the at a dose that increased bulk histone acetylation, treatment with 
the HDACi, SB, improves behavioral despair in mice.   It is remarkable that SB-mediated 
antidepressant action was apparent one day (23 hrs) after the preceding dose, 
notwithstanding that SB-mediated acetylation of brain histones had returned to baseline 
levels within the first hour post-injection. This finding raises the question as to which 
molecular mechanisms contribute to the observed long-term behavioral changes after SB 
treatment.  
Finally, it should be noted that, in support of my hypothesis, combined treatment 
with a hyperacetylating dose of SB in combination with fluoxetine was, in terms of 
antidepressant-like effects, superior to fluoxetine alone.  This treatment was further in 
support of my hypothesis as it was associated with increased BDNF transcript in the 
frontal cortex of mice (albeit transiently) when compared to saline treated controls.  Thus, 
the combination of a broad-acting, or brain region-selective (Simonini et al., 2006) 
HDACi together with an SSRI may eventually be a promising novel antidepressant 
treatment strategy that warrants further exploration in experimental animal models.  
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Fig. 2-1: Drug treatments and timeline. 
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Fig. 2-2:  SB injection (i.p.) induces transient histone hyperacetylation in bulk chromatin 
from liver and hippocampus.  
(A) Top: Representative immunoblot of liver protein extract from SB and saline (Sal) 
treated animals, labeled with anti-acetyl H3 (upper band) and, for loading control, anti-
H4 antibody (lower band)  Bottom: Line graph showing temporal course of H3 
acetylation in liver, after a single i.p. dose of 1.2g/kg SB (N= 5-7 / time point and 
treatment group).  Data (mean +/- S.E.) are expressed relative to saline-treated controls, 
after normalization to histone H4.  Notice increased levels of H3 acetylation within the 
first 30min after drug injection, followed by return to, or slightly below baseline levels 
thereafter.  (B) Kinetics of hippocampal H3 acetylation from the same animals shown in 
(A).  Notice that drug-induced H3 acetylation peaks at 30min, and returns to baseline at 
60min post-injection. (C) Top: Representative hippocampal immunoblots from animals 
treated with 0.2, 0.4, or 1.2g/kg SB or saline.  Acetylated H3 (upper band), modification-
independent H4 for loading control (lower band).  Bottom: Line graph showing dose-
dependent increase in hippocampal H3 acetylation. Notice significant increase in H3 
acetylation at the two highest doses (0.4 and 1.2g/kg). (D) Histone immunoblots 30 min 
after sodium butyrate injection; (Left) hippocampus, showing acetylated H4 and 
Coomassie blue as loading control and (Right) frontal cortex showing acetylated H3 and 
total H4 immunoreactivity for loading control. (A-C) N=5/ dose/timepoint, * p < 0.05;  
compared to saline-treated animals. 
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Fig 2-3:  Behavioral measures of anxiety and despair after chronic treatment with SB.   
(A-C) Bar graphs summarizing results from a battery of four tests (see Fig. 1) in animals 
treated with SB high dose (SB-H; 1.2 g/kg; black bars) or low dose (SB-L; 0.2 g/kg; gray 
bars) or saline-treated controls (white bars). Data are represented as mean +/- S.E. (A) 
Tail suspension test (TST), left graph: latency to first cross; right: total freeze time. 
Notice significant decrease in immobility scores in high dose (SB-H) SB group; N = 32-
34/treatment group, * (**) p<0.05 (0.01), ANOVA, post hoc Tukey. (B) Open field test, 
left graph: time in thigmotaxis zone (sec); right: average speed (cm/sec).  (C) Light-dark 
(LD) box, graphs (left to right) show latency to first cross, total crossings and total time 
in dark side. Notice lack of significant changes in forced swim and open field, and no 
consistent effect in LD test. 
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Fig 2-4:  Chronic co-treatment with SB and fluoxetine decreases immobility in the TST.  
(A-C) Bar graphs summarizing results from battery of four tests (see Fig. 1) in animals 
treated with (i) SB (0.6g/kg) plus fluoxetine (10 mg/kg) (dark gray bars) or (ii) with 10 
mg/kg fluoxetine as single drug (light gray bars) or (iii) saline (white bars). Data are 
represented as mean +/- S.E. (A) Tail suspension test (TST), left (right) graph shows 
latency to first cross (total freeze time). Notice significant decrease in immobility scores 
in group treated with SB plus fluoxetine. (B) Panel B as in Fig. 3. (C) Light-dark (LD) 
box, graphs (left to right) show latency to first cross, total crossings and total time in dark 
side. Notice lack of significant changes in LD (C), and no consistent anti-anxiety effect 
by open field test (B). N = 18-24/treatment group, * (**) p<0.05 (0. 01), ANOVA, post 
hoc Tukey. 
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Fig 2-5: Behavioral despair measures after acute treatment with SB and/or fluoxetine.   
(A,B) Bar graphs summarizing data (mean +/- S.E.) from TST 30 min after acute 
injection (i.p.) of (A) (i) SB (0.6 g/kg) plus fluoxetine (10 mg/kg) (dark gray bar), (ii) 
fluoxetine 10 mg/kg as single drug (light gray bar) or saline as control (white bar), and 
(B) SB (1.2 g/kg) as single drug (striped bar), in comparison to saline. Notice robust 
decrease in immobility scores in animals co-treated with SB and fluoxetine (A). N = 10-
12/treatment group, * (**) p<0.05 (0. 01), ANOVA with post hoc Tukey. 
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Table 2-1:  Levels of hippocampal BDNF after acute and chronic treatment with SB 
and/or fluoxetine.  
Data (mean ± S.E.) show fold-changes in comparison to saline-treated animals, after 
normalization to 18S ribosomal RNA in hippocampus (HIP) and frontal cortex (FC). 
Notice significant increase in frontal BDNF mRNA levels 30 min after acute fluoxetine 
and 120 min after chronic co-treatment with fluoxetine + SB. Notice further the 
significant decrease in HIP after chronic treatment with fluoxetine ± SB. E= ELISA. * 
(**) p < 0.05 (0.01). 
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 Supplemental Fig. 2-1: A.  BDNF qRT-PCR melting curve control.  Single peak 
suggests single amplicon, particularly in comparison to water template (no derivative 
peak).  B.  BDNF qRT-PCR amplification plot, with primers/template combinations 
indicated in key; illustrates very low contamination of reagents with nuclear material 
(pentagon, arrow) and accurate results (tight clustering of data within other shapes). 
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CHAPTER III: 
Drug-induced Activation of Dopamine D1-Receptor Signaling and Inhibition of 
Class I/II Histone Deacetylase Induces Chromatin Remodeling in Reward Circuitry 
and Modulates Cocaine-Related Behaviors 
The work presented in this chapter is reproduced from a study by Schroeder et al., 
published in Neuropsychopharmacology (Schroeder et al., 2008). 
This work was conducted under the direction of Dr. Schahram Akbarian, and it is 
with gratitude to him and the other authors that I reproduce these data for the purposes of 
this dissertation with minor changes in style and text.  My contributions to this work 
consisted of leading treatment and preparation of brain samples for all (non-HPLC) 
mouse biochemical experiments, western immunoblotting of in vivo samples, 
immunohistochemistry, and assisting with ChIP and qPCR execution (Fig.3-2, 3-3, and 
3-4A-C, and Supplemental Fig. 3-1, 3-2 and 3-4). In the preparation of the manuscript, 
prepared together with Dr. Akbarian, I was responsible for preparation of all figures, 
figure legends and statistics, as well as major contributions to the Results, Materials and 
Methods sections in addition to providing feedback on other sections.  Krista Penta 
contributed the mouse behavioral testing.  Anouch Matevossian contributed by assisting 
greatly in the ChIP and qPCR experiments.  Dr. Sara Jones contributed by conducting 
HPLC experiments.  Dr. Christine Konradi contributed by conducting in vitro 
immunoblotting experiments.  Dr. Andrew Tapper led design of the behavioral testing 
and assisted in statistical analysis.  
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ABSTRACT 
Chromatin remodeling, including histone modification, is involved in stimulant-induced 
gene expression and addiction behavior.  However, to date, the impact of HDAC activity 
on an animal’s behavior response to stimulant drug has been assessed following repeated 
administration to cocaine – a drug known to affect multiple neurotransmitter systems.  To 
further explore the role of dopamine D1 receptor signaling, we measured cocaine-related 
locomotor activity and place preference in mice pre-treated for a period of 10 days with 
the D1-agonist SKF82958 and/or the histone deacetylase inhibitor (HDACi), sodium 
butyrate. Co-treatment with D1-agonist and HDACi significantly enhanced cocaine-
induced locomotor activity and place preference, in comparison to single drug regimens.  
However, butyrate-mediated reward effects were transient and only apparent within 2 
days after the last HDACi treatment. These behavioral changes were associated with 
histone modification changes in striatum and ventral midbrain: (1) a generalized increase 
in H3 phospho-acetylation in striatal neurons was dependent on activation of D1 receptors 
and (2) H3 de-acetylation at promoter sequences of tyrosine hydroxylase (Th) and brain-
derived neurotrophic factor (Bdnf) in ventral midbrain, together with up-regulation of the 
corresponding gene transcripts after co-treatment with D1-agonist and HDACi. 
Collectively, these findings imply that D1-receptor-regulated histone 
(phospho)acetylation and gene expression in reward circuitry is differentially regulated in 
a region-specific manner. Given that the combination of D1-agonist and HDACi enhances 
cocaine-related sensitization and reward, the therapeutic benefits of D1-receptor 
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antagonists and histone acetyl-transferase inhibitors (HATi) warrants further 
investigation in experimental models of stimulant abuse.  
INTRODUCTION 
To date, the molecular mechanisms that underlie cocaine and other stimulant addiction 
become increasingly clear but current pharmacological treatment options remain 
surprisingly limited.  Therefore, it will be important to further elucidate the molecular 
pharmacology of cocaine addiction in pre-clinical models. Among the various drug-based 
interventions that modulate the animal’s response to cocaine are two radically different 
classes of compounds – dopamine D1 receptor agonists and histone protein deacetylase 
inhibitors (HDACi).  Notably, D1 agonist drugs elicit reward functions, including 
reinstatement of cocaine-related addiction behavior (Self and Stein, 1992, Graham et al., 
2007) and the importance of D1-mediated signaling for the neurobiology of stimulant 
abuse is established by various genetic and pharmacological approaches (Hummel and 
Unterwald, 2002). Importantly, the neurochemical and behavioral adaptations in response 
to stimulant or D1 agonist exposure are thought to result, at least in part, from changes in 
gene expression affecting dopaminergic circuitry, including ventral midbrain and the 
striatum and other major target zones within the forebrain. Recently, it was recognized 
that among these cocaine-sensitive transcriptional mechanisms, histone acetylation and 
other histone modifications are of particular importance; for example, pharmacological 
inhibition or genetic ablation of class I/II histone deacetylases enhances cocaine-related 
behavioral sensitization and reward (Kumar et al., 2005, Renthal et al., 2007). 
Conversely, striatal overexpression of histone deacetylase (HDAC) or genetic ablation of 
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histone acetyl-transferases, including Cbp, attenuates the animal’s response to cocaine 
(Kumar et al., 2005, Levine et al., 2005).  
However, it is not known whether or not these two reward-enhancing drug types – 
D1 receptor agonists and HDAC inhibitors operate synergistically or independently. 
Therefore, it was the goal of this study to understand how drug-induced changes in D1-
receptor signaling and histone deacetylase activity modulate the animal’s behavioral and 
molecular responses to cocaine. Specifically, I hypothesized that sensitization of the 
dopaminergic system by combined treatment of SB with the dopamine D1-receptor 
agonist, SKF82958 (SKF), would enhance an animal’s behavioral response to subsequent 
cocaine challenge.  I also proposed that SB+SKF combination treatment would be 
associated with changes in transcription of tyrosine hydroxylase and BDNF in addition to 
chromatin modification changes in the promoter regions of these genes.  We applied, in 
C57Bl/6J mice, two cocaine-related behavioral assays – locomotor sensitization and 
place preference. The molecular studies were conducted on ventral midbrain at the level 
of the substantia nigra/ventral tegmental area (SN/VTA) and striatum (including but not 
limited to the nucleus accumbens)(Winder et al., 2002, Kalivas and Volkow, 2005) – two 
key regions of the brain’s reward circuitry. Specifically, we examined drug-induced 
changes in nucleosome core histone H3 and H4 acetylation and phospho-acetylation, two 
types of modifications previously linked to changes in dopaminergic signaling (Li et al., 
2004, Brami-Cherrier et al., 2005, Kumar et al., 2005, Levine et al., 2005, Santini et al., 
2007).  
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Our results indicate that combined D1 receptor activation and HDAC inhibition 
was associated with a heterogeneous set of region-specific histone modification 
mechanisms, including a generalized histone phospho-acetylation response in striatal 
neurons and histone deacetylation in SN/VTA chromatin at promoters of tyrosine 
hydroxylase (Th) and brain-derived neurotrophic factor (Bdnf) – two genes with a key 
role for drug-induced plasticity(Self et al., 2004, Corominas et al., 2007). However, 
changes in cocaine-related behaviors after previous exposure to D1 agonist with or 
without HDACi co-treatment were complex, because the two different types of drugs 
exerted a synergistic effect in some but not all behavioral assays. These differences were, 
at least in part, explained by the observation that butyrate-mediated reward effects were 
transient and only apparent within 2 days after the last HDACi treatment. 
 
Methods and Materials 
Drugs 
SB, or N-Butyric Acid sodium salt, and SKF, or Chloro-APB Hydrobromide (±)-SKF-
82958 hydrobromide, or cocaine  (Sigma-Aldrich) were dissolved in saline and prepared 
fresh each day. For this study, SKF was chosen as a full D1-like agonist and SB was 
chosen as a class I/II HDAC inhibitor. Other drugs included in this study were the PKA 
inhibitor N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide 
dihydrochloride, (H89) and the NMDA receptor antagonist [(+)MK 801 hydrogen 
maleate] (MK-801), both dissolved in DMSO. 
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Animals 
All experimental procedures were approved by the Institutional Animal Care and Use 
Committee of the University of Massachusetts.  For all experiments with the D1 receptor 
agonist SKF82958, male C57BL/6J mice, age 9-15 weeks, were used. Animals were 
purchased directly from the Jackson Laboratory, Bar Harbor (Maine), and housed in 
groups of 2-4 per cage with food and water ad libitum under 12-hour light/dark cycle. For 
behavioral experiments, mice received i.p. injections with SB (100mg/kg or 25 mg/kg) or 
saline followed 15 min later by SKF (0.25mg/kg) or saline once daily for 10 days. For the 
remaining experiments, mice received i.p. injections with  SKF (1 mg/kg) or saline as 
vehicle, with or without concomitant SB (200mg/kg or 25 mg/kg), as single dose or once 
daily for 2-10 days. 
For tissue extraction, animals were sacrificed by cervical dislocation/decapitation and 
whole brain was removed and processed immediately or snap-frozen on dry ice.  Striatum 
was dissected unilaterally from coronal slices positioned between Bregma 1.18mm and –
0.46mm; Ventral midbrain was dissected from coronal slices positioned between Bregma  
-2.80mm and –3.80mm and ventral to the dorsal 3rd ventricle; the dissected blocks of 
tissue thus included the full rostro-caudal and dorso-ventral extent of the substantia nigra 
and the ventral tegmental area (SN/VTA) (Paxinos and Franklin, 2001a). 
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Behavioral Testing 
Tests were conducted during the light cycle between 7:30am and 2:30pm.  Depending on 
the drug and test, 8-10 animals per experiment were used, with a matched number of 
saline-treated control subjects. 
Locomotor activity.  Animals were placed in clean, 19.1x29.2x12.7cm shoebox-style 
cages (Allentown, Inc., Allentown, NJ) and locomotor activity measured continuously for 
190 min (from t = 0 min to t = 190 min) using a photobeam activity system (San Diego 
Instruments, San Diego, CA).  All mice were placed in activity cages and allowed to 
habituate for 75 minutes prior to any injection.  To assay the effects of SB and SKF 
pretreatment on cocaine-induced locomotion, mice were first introduced to the test and 
injected with saline at t = 90 min to record basal activity (day zero).  The next day, a 10-
day pretreatment period was initiated with daily i.p. injections of: i, Sal+SKF; ii, 
SB+SKF; iii, SB+Sal; or iv, Sal+Sal, each at t = 75 min  and t = 90 min, respectively.  
During pretreatment, activity was measured on days 1, 2, 5, 7 and 10.  On day 11, 
animals were placed in activity cages, saline injected at t = 75 min followed by cocaine 
(15mg/kg) at t = 90 min, and activity measured for 190 min total. 
 
Conditioned Place Preference.   
The conditioned place preference (CPP) test apparatus consisted of a rectangular cage 
with overall inside dimensions of 46.5 x 12.7 x 12.7cm (med-associates, St. Albans, VT). 
This included a center neutral gray compartment, 7.2cm long, and a hinged clear 
polycarbonate lid for loading the test animal. The adjacent conditioning compartments 
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measured 16.8 cm long. One compartment was black with a stainless steel grid rod floor 
and the other white with a square stainless steel mesh floor in order to make the context 
of each chamber as different as possible for counterbalancing drug-independent place 
preference.  Chambers were equipped with photobeams to measure activity and time 
spent in each chamber.  Guillotine doors separated the chambers and could be fixed in the 
closed or opened position.  The apparatus was placed in a sound attenuation cubicle.    
Two cocaine-related CPP paradigms were used in the present study, with the main 
difference being the timeline of SKF and SB treatments:  
Paradigm 1: Preceding CPP testing, all animals were treated for 10 days with daily 
injections of: Sal+SKF or SB+SKF or Sal+Sal as described above.  Then, CPP was tested 
in three stages over a 6-day period. In the first stage, each mouse was placed in the 
central compartment and allowed free access to all chambers. The time spent in each 
chamber was then recorded over a 20 min period.  During the second stage, i.p. injections 
of cocaine (5mg/kg) were paired with one of the conditioning chambers and saline 
injections paired with the other.  Each mouse received cocaine injections and was placed 
in the isolated cocaine-conditioning chamber on day 3 and 5; each mouse received saline 
injections and was placed in the saline chamber on day 2 and 4.  Each training trial lasted 
20 min.  During stage 3, the testing phase, each mouse was once again given free access 
to all chambers for 20 min.  The time spent in each chamber during stage 1 (baseline) was 
subtracted from the time spent in each chamber during stage 3.  A preference toward the 
cocaine-associated chamber compared to baseline is a measure of the reward behavior 
associated with cocaine.  Control mice received saline in both chambers.  Mice that 
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exhibited an initial bias for the white or black chamber received cocaine in the least-
preferred chamber.   
Paradigm 2: In contrast to paradigm 1, no pre-treatment were administered and animals 
were subjected to the first (baseline, day 1) and second stage (saline, days 2 and 4; 
cocaine, days 3 and 5) of CPP training as described above. In addition, on days 1, 2 and 
4, animals received within one hour after the training session SKF ± SB at the same doses 
described above. 
Cell culture studies 
Primary striatal cultures were prepared as described previously, with minor modifications 
(Konradi et al., 1996, Rajadhyaksha et al., 1998).  Striata from 18-d-old Sprague Dawley 
rat fetuses were dissected and resuspended in defined medium [50% F12/DMEM and 
50% DMEM (Gibco-Invitrogen, Grand Island, NY) with the following supplements per 
liter of medium: 4 gm of dextrose, 1X B27, 10 ml of penicillin-streptomycin liquid 
(Gibco-Invitrogen), and 25 mM HEPES]. Cells were resuspended in defined medium to 
1.2x 106 cells/ml and plated in 12-well plates (Costar, Cambridge, MA) at 2 x106 
cells/well. Plates were pretreated with 1 ml of a 1:500-diluted sterile solution of 
polyethylenimine in water for 18 hr, washed twice with sterile water, coated with 2.5% 
serum-containing PBS solution for at least 4 hr, and aspirated just before plating.  All 
experiments were performed in triplicate with cells 6 d in culture and repeated at least 
once in an independent dissection. As determined by HPLC analysis, glutamate levels in 
the medium on the day of the experiments ranged from 1 to 5 µM. The neuron to 
astroglia ratio was below 25:1, as established by immunocytochemical staining with the 
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glial fibrillary acid protein (Dako, Carpinteria, CA) and counterstaining with 1% cresyl 
violet. All drugs used for the in vitro experiments were purchased from Sigma.  At two 
different time points prior to harvest – 3 hours and 30 minutes – cells were treated with 
one of the following drugs (treatment #1): (1.1) vehicle (10 uL DMSO); (1.2) the PKA 
inhibitor N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide 
dihydrochloride, (H89), 20 µM; (1.3) the NMDA receptor antagonist [(+)MK 
801 hydrogen maleate] (MK-801), 2 µM. Three hours before harvest, cells were treated 
with one of the following drugs (treatment #2): (2.1) vehicle (10 µL water); (2.2) Sodium 
butyrate (10µM to 10mM); (2.3) SKF82958 (50 µM). 
 Western blotting 
 Striatal tissue was homogenized in Laemmli buffer, then incubated at 37°C for 10min, 
centrifuged at 13,500g at 4°C; the supernatant was denatured at 95°C for 5min, then 
electrophoresed on a 10-20% linear gradient Tris-HCl gel (Bio-Rad) and transferred to 
PVDF membrane (0.2uM pore size, Bio-Rad).  Immunolabelings were performed with 
anti-phospho (Ser10)-acetyl (Lys14)-histone H3 antibody (#07-081), anti-phospho 
(Ser10)-histone H3 antibody (#05-598); anti-acetyl-histone H3 antibody  (#06-599), and 
recognizing total histone H4 as loading control, the anti-histone H4 antibody (#07-108), 
all from Upstate, Lake Placid, NY.  Additional blots were probed with anti-tyrosine 
hydroxylase (#T-2928), Sigma-Aldrich, St. Louis, MO and anti-phospho (Ser31)-tyrosine 
hydroxylase (#36-9900), Zymed Laboratories-Invitrogen.  Immunoreactivity was 
detected using peroxidase-conjugated secondary antibody (donkey anti-rabbit IgG or 
sheep anti-mouse, Amersham) in conjunction with chemiluminesence-based film 
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autoradiography (Super Signal West Dura Extend Reagent, Pierce).  For quantification, 
Quantity One software was used (Biorad).   
Immunohistochemistry  
Coronal sections (14 µm) were cut from blocks containing striatum and collected in ice-
cold PBS for free-floating immunohistochemistry. Sections were blocked in 0.3% Triton 
X-100/± 2% goat serum/0.1M sodium phosphate (pH 7.4).  Sections were next incubated 
in 0.3% Triton X-100 / 0.1 M sodium phosphate buffer and the anti-phospho (ser10) -
acetyl (Lys9)-histone H3 antibody (1:500, #ab4272, Abcam, Cambridge, MA) together 
with the monoclonal anti-NeuN antibody (1:300, #MAB377, Chemicon, Temecula, CA) 
overnight at 4°C, washed, then incubated with Texas-Red-conjugated horse anti-mouse 
antiserum and FITC-conjugated goat anti-rabbit antiserum (1:200, Vector) for 60 min at 
RT, washed, slide-mounted, dried, counterstained with 4,6,-diamidino-2-phenylindole 
dihydrochloride (DAPI) and coverslipped with Vectashield (Vector). Sections were 
examined with a Zeiss Axiovert microscope and digitized images were obtained with 
OpenLab software (Improvision, Lexington, MA).  
Quantitative RT-PCR 
From each animal, total RNA from striatum or ventral midbrain was extracted using the 
trizol-based RNeasy Lipid Tissue mini kit (QIAGEN).  Amplification reactions were 
performed in triplicate, using the ABI PRISM 7500 Real Time PCR System (Applied 
Biosystems) in conjunction with the One-Step RT-PCR kit (Applied Biosystems), SYBR 
green as a reference dye and the following cycling protocol: 48°C, 30min; 95°C, 10min; 
followed by 45 cycles of 95°C 15s, 60°C 1min.  Primer sequences were designed to 
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amplify 90-150bp fragments from respective gene coding regions: Tyrosine Hydroxylase 
(Th) primer sequences (94bp product): forward, attggaggctgtggtattcg; reverse, 
cgagacagtgaggagggttt.  Bdnf primer sequences (118bp product), forward 
gcgcccatgaaagaagtaaa, reverse tcgtcagacctctcgaacct.  C-fos primer sequences (147bp 
product), forward, atccttggagccagtcaaga; reverse, gcatagaaggaaccggacag.  β2 
microglobulin (B2m) primer sequences (98bp product), forward, tggtgcttgtctcactgacc; 
reverse, tatgttcggcttcccattct.  A 133bp fragment from mouse 18S rRNA was amplified in 
parallel reactions for normalization. 18S rRNA primer sequences: forward, 
catggccgttcttagttggt; reverse, gaacgccacttgtccctcta.  For additional information on PCR 
primers and products, see Supplemental Table. Quantification and normalization 
procedures were previously described (Stadler et al., 2005). 
Chromatin Immunoprecipitation and Quantitative PCR 
Ventral midbrain tissue (30mg, pooled from 2-3mice) was homogenized and digested 
with micrococcal nuclease for further application to native chromatin 
immunoprecipitation (ChIP) with anti-acetyl-histone H3 (Upstate #06-599) or anti-acetyl-
histone H4 (Upstate #06-598) antibodies or the control antibody against total histone H4, 
anti- H4 (Upstate #07-108) and anti-H3 (Abcam Ab1791-100) followed by quantitative-
PCR (qPCR) as previously described (Huang et al., 2006). Primers were selected 
upstream of respective gene transcription start sites (TSS), with product sizes in the range 
of 75-125bp in order to amplify from mononucleosomal DNA (147bp).  Three primers 
were designed to amplify sequences proximal to the tyrosine hydroxylase promoter 
region: Th-a, forward, ttgaagacacagcctgcaac; reverse, ggggaggtcagaagacccta, (70bp 
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product, -652bp from TSS = 150085865; NC_000073.5); Th-b, forward, 
acggaggcctctctcgtc; reverse, gtcccccacctcctacctc; (103bp product, -91bp from TSS = 
150085865; NC_000073.5); and Th-c, forward, ctggggtatccacccattta; reverse, 
gccgtctcagagcaggatac (113bp product, +48bp from TSS = 150085865; NC_000073.5).  
Three primers were designed to amplify sequences from the non-coding BDNF promoter 
regions pI, pIII, and pIV: pI, (106bp product, forward, tggagacccttagtcatggtg; reverse, 
gcctctctgagccagttacg; pIII, 129bp product, forward, aatgtgcagtggggaaagag; reverse, 
ggcagggataccgagagaat; pIV, 114bp product, forward, aaatggagcttctcgctgaa, reverse, 
agtctttggtggccgatatg).  Primers were designed for the housekeeping gene β2 
microglobulin, B2m, forward, gggaaagtccctttgtaacct, reverse, gcgcgcgctcttatatagtt 
(112bp product, -57bp from TSS = 121973475; NC_000068.6). For additional 
information on PCR primers and products, see Supplemental Table. 
 
Statistical Analysis  
Biochemical data (immunoblots, quantitative PCR) from experiments with two groups 
were compared using Student’s T-test.  For experiments with three or more groups, 
comparisons were made with one-way ANOVA and the Tukey-Kramer or Least-
Significant Differences tests for post hoc comparison (SYSTAT). Significance in all 
behavior experiments was determined by one- or two-way ANOVA followed by post-hoc 
analysis (Tukey test unless otherwise stated). 
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Results 
Systemic Pretreatment with D1-agonist and HDACi Enhances Cocaine-induced 
locomotor activity and reward 
 We first examined whether cocaine-induced locomotion is affected by previous 
exposure to the D1/D5 agonist, SKF82958. The drug was administered once daily (0.25 
mg/kg i.p.) for 10 days and 24 hours after the last dose, animals received a single dose of 
cocaine (15 mg/kg i.p.).  Comparison of locomotor activity of mice pre-treated for 1-10 
days with SKF±SB (2-way ANOVA) revealed significant main effects due to treatment 
[FSB+SKF vs Sal+SKF (1,70) = 10.1, p<0.01] and time [FSB+SKF vs Sal+SKF (4,70) = 13.3, p<0.001, but 
no significant interactive effect between treatment and time [FSB+SKF vs Sal+SKF (4,70) = 
0.962, p=0.434] (Fig. 3-1A). Furthermore, in comparison to animals pre-treated with 
saline, exposure to D1-agonist resulted in a more than 2-fold increase in cocaine-induced 
locomotion (Fig. 3-1B), which is in agreement with previous studies (Pierce et al., 1996, 
De Vries et al., 1998, Sorg et al., 2004). Importantly, this cocaine-related locomotor 
sensitization was even further enhanced – up to 5-fold when compared to saline controls - 
in animals pre-treated for 10 days with D1 agonist plus SB (100 mg/kg) (Fig. 3-1B). The 
cocaine-induced activity in the group co-treated with 100 mg/kg SB+SKF was also 
significantly increased compared to mice pretreated with SKF as single drug (Fig 3-1C) 
[FSB+SKF vs Sal+SKF (3,28) = 33.39, p < 0.001]. Notably, 100 mg/kg SB administered as single 
drug was indistinguishable from saline (Fig. 3-1B,C). Furthermore, SB+SKF co-
treatment with a lower dose of SB (25mg/kg) was indistinguishable from the SKF single 
drug regimen (Fig. 3-1C). We conclude that pre-treatment with D1 agonist and the 
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HDACi, SB, results in a synergistic and dose-dependent locomotor activity effect of a 
subsequent dose of cocaine administered 24 hours later.  
 Next, we wanted to examine whether or not previous exposure to D1 agonist and 
HDACi results in sustained (long-term) changes in cocaine-related reward behavior. To 
examine this, we treated three groups of mice for 10 days either with (i) saline or (ii) SKF 
82958 (0.25 mg/kg), (iii) SKF plus SB (100 mg/kg). Then, animals were subjected for a 
6-day period to a place preference paradigm (CPP, paradigm 1, see Methods) to 
distinguish the rewarding effects of cocaine (5 mg/kg) from saline (see Methods for 
details). On the 6th and final CPP day, animals that had been pre-treated with SKF 
showed a significant increase in preference for the cocaine chamber (Fig. 3-1D), which is 
in good agreement with a recent report in rats (Graham et al., 2007). However, in this 
paradigm, co-treatment with SB was not more effective than single drug SKF (Fig. 3-
1D), and therefore we conclude that exposure to the D1 agonist but not the HDACi 
induced a sustained change in behavioral plasticity as it pertains to cocaine-related 
preference behavior. 
 The above CPP results suggest that repeated exposure to D1 agonist, but not SB 
induces sustained changes in reward circuitry that lasted at least 6 days. Next, we wanted 
to find out whether or not SB enhances cocaine reward of animals that receive a much 
shorter course of SKF treatments.  Therefore, in CPP paradigm 2, no pre-treatment with 
SKF or SB was administered, and instead these drugs were administered during the 
training period and cocaine reward was evaluated 48 hours after the last dose of SKF ± 
SB (see Methods). Indeed, in paradigm 2, mice treated with SKF+SB showed significant 
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cocaine-related place preference. This effect was not seen in animals that received single 
drug SKF (Fig. 3-1E). We conclude that exposure to SB enhances cocaine-related reward 
of D1-agonist within a shorter time frame. 
 
Exposure to D1 agonist and HDACi is associated with increased gene expression in 
ventral midbrain and histone modfication at selected promoter sequences 
   To find out whether the increased cocaine-related locomotion in animals pre-
treated with SKF82958 and SB is associated with changes in gene transcription in ventral 
midbrain and striatum as key structures of the reward pathway, we assayed mRNA levels 
for (i) tyrosine hydroxylase (TH) (Belin et al., 2007) the rate limiting enzyme in 
catecholamine biosynthesis, (ii) brain-derived neurotrophic factor (BDNF), a nerve 
growth factor molecule thought to play an important role in the neurobiology of cocaine 
addiction (Guillin et al., 2001, Hall et al., 2003, Graham et al., 2007), (iii) c-fos, a 
prototype early response gene and (iv) β2-microglobulin, a “housekeeping gene”, as a 
control. For each gene (i) – (iv), transcript levels were determined by qRT-PCR and 
normalized to 18S rRNA levels which differed less than 5 – 10% between groups, with 
no consistent effect by treatment. 
Notably, animals that received 10 daily doses of SKF + 100 mg/kg SB (i.e., the 
treatment associated with the highest degree of locomotion upon subsequent exposure to 
cocaine, see Fig. 1B,C) showed significantly higher levels of Th and Bdnf mRNA levels 
in ventral midbrain, in comparison to SKF+Sal treated animals [F (3,15)SB+SKF vs Sal+SKF = 
9.586TH , p<0.03; = 8.891BDNF , p<0.04] (Fig 3-2A).  In contrast, ventral midbrain B2m 
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mRNA levels, and all striatal transcripts were indistinguishable between animals that 
received SB or Sal as co-treatment together with SKF (Fig. 3-2A). We conclude that the 
locomotor-activating effects of the HDACi, SB, are associated with transcriptional 
changes in ventral midbrain.   
Next, we wanted to examine if the increases in ventral midbrain Th and Bdnf 
mRNA levels in the SKF+SB treated animals are associated with changes in histone 
modification events at the corresponding promoters. Importantly, transcriptional profiling 
by microarray consistently revealed that after treatment with class I/II HDACi, a nearly 
equal number of genes show decreased or increased expression (Mariadason et al., 2000, 
Nusinzon and Horvath, 2005, Chen and Cepko, 2007). Furthermore, it is possible that – 
in addition to their established function in transcriptional repressor complexes (Butler and 
Bates, 2006) HDAC activity is necessary to maintain transcriptional activity at selected 
genomic loci (Dehm et al., 2004).  These novel findings suggest that both increased, or 
decreased histone acetylation in a promoter chromatin environment could potentially be 
associated with increased gene expression levels.  Therefore, we monitored histone H3 
acetylation levels at Th, Bdnf, and B2m gene promoters. Immunoprecipitation of ventral 
midbrain prepared by micrococcal nuclease digestion showed that one out of three sites 
within close proximity to the Th transcription start site (Fig. 3-2B, a-c) had a significant 
decrease in H3 acetylation in 1mg/kg SKF + 200 mg/kg SB treated animals compared to 
saline controls. The H3 acetylation changes after co-treatment with SKF and the higher 
SB dose were specific because H4 acetylation at this portion of the Th promoter was 
unchanged (Suppl. Figure 1). This particular finding may not be too surprising given that 
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differential regulation of H3 and H4 acetylation has been noted before both in cell lines 
(Rada-Iglesias et al., 2007) and brain tissue (Kumar et al., 2005, Chwang et al., 2007). 
Moreover, SB-induced H3 acetylation changes were dose dependent, because co-
treatments with 1 mg/kg SKF + 25 mg/kg SB did not result in significant histone 
acetylation changes at the Th promoter (Suppl. Figure 3-2).  
Furthermore, we measured histone H3 acetylation in chromatin surrounding Bdnf  
- a gene with complex transcriptional regulation, multiple promoters and non-coding 
exons (Timmusk et al., 1993).  For example, increased Bdnf expression after 
antidepressant treatment involves exon I (Russo-Neustadt et al., 2000, Dias et al., 2003).  
Moreover, dramatic increases in exon III and IV expression were observed in an animal 
model for social stress (Tsankova et al., 2006a).  Given this background, we determined 
H3 acetylation at the Bdnf for each promoter of the non-coding exons I, III and IV.  
Chromatin from ventral midbrain of SB+SKF-treated mice showed, in comparison to 
saline treated controls, no changes in H3 acetylation at Bdnf promoters PI and PIII (Fig. 
3-2B). However, ventral midbrain chromatin from the SKF + SB treated animals showed 
a significant down-regulation of H3 acetylation at Bdnf promoter IV at the higher SB 
dose of 200 mg/kg (Fig. 3-2B) but not after 25mg/kg SB (Suppl. Figure 3-2). 
Furthermore, changes in H4 acetylation were more variable (Suppl. Figure 3-1). 
Furthermore, there were no significant acetylation changes at the B2m promoter (Fig. 3-
2B). Taken together, our result show that in ventral midbrain, up-regulated expression of 
Th and Bdnf in response to D1 agonist and HDACi co-treatment is associated with histone 
H3 deacetylation events of selected portions of the corresponding gene promoters. Given 
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that our immunoprecipitation assays were performed on mononucleosomal chromatin 
preparations from ventral midbrain (see Methods), we wanted to find out whether a 
decrease in nucleosomal densities underlies the observed histone hypoacetylation at 
selected sequences of the Th and Bdnf promoters in the SB+SKF treated animals. We 
therefore conducted ventral midbrain ChIP with an antibody recognizing total H4 or an 
antibody raised against the C-terminus of histone H3; however SKF+SB treated animals 
showed, in 5 out of 6 experiments, an increase in nucleosomal densities at the Th 
promoter sequence “a”  (see also Fig. 2B) and similar changes at Bdnf promoter IV, in 
comparison to saline-treated controls (data not shown).  Therefore, the observed decrease 
in histone acetylation - which was approximately 0.5-fold for Th and Bdnf (Fig. 3-2B) - 
cannot be explained in terms of dispersion or decrease in nucleosome density.  
 
Co-treatment with D1 agonist and HDACi is associated with a transient up-
regulation of Th protein in striatum 
To find out whether the observed changes in gene expression and histone acetylation at 
the Th promoter in ventral midbrain occur in conjunction with alterations in TH protein 
levels, we assayed TH protein levels, including its phospho-activated form, phospho-
Ser31-TH (Moy and Tsai, 2004).  Animals were sacrificed 30 min after acute or chronic 
treatment (see Methods), which corresponds to the time (post-injection) at which changes 
in locomotor activity were observed.  We assayed two brain regions, the SN/VTA and 
striatum including nucleus accumbens and caudate-putamen, a cocaine-sensitive target 
for dopaminergic fibers (Graybiel et al., 1990, Winder et al., 2002). In the striatum, 
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significant changes were limited to the group of animals treated with SB + SKF, which 
showed a 2-fold increase in TH immunoreactivity when compared to saline-treated 
controls  (Fig 3-3A, [FSB+SKF vs Sal+Sal (3,32) = 2.936, p < 0.01]). In contrast, animals treated 
with single drug SKF or SB did not show significant changes (Fig. 3-3A). Likewise, 
significant changes in striatal phospho-Ser31-TH were limited to the group of SKF+SB 
treated animals, which showed a 30% increase compared to animals treated with single 
drugs.  These changes were significant [FSB+SKF vs SKF+Sal or SB+Sal (3,32) = 2.312, p < 0.040] 
(data not shown). In contrast to the significant up-regulation of striatal TH 
immunoreactivity in the SKF+SB treated animals, levels of TH protein in ventral 
midbrain remained unaffected (Fig. 3-3B).  Furthermore, the observed increase in striatal 
TH after SKF+SB was transient because it was apparent at 30 min (Fig. 3-3A) but not 6 
days (Fig. 3-3C) after the last of 10 daily treatments. We conclude that repeated exposure 
to D1-agonist and HDACi is associated with a transient increase in striatal TH protein. 
Furthermore, we assayed the concentration of dopamine and its metabolite, DOPAC, by 
HPLC and no significant differences between treatment groups were observed (Suppl. 
Figure 3). This would suggest that an increase in striatal TH (including phospho-TH) is 
not necessarily reflected by a net change in dopamine tissue levels.    
 
Activation of D1-signaling is linked to a nucleosomal response in striatum 
Based on the findings of the present study, repeated treatment with SKF+SB selectively 
induces gene expression changes and histone modification in ventral midbrain, and this 
occurs in conjunction with an increase in locomotor activity upon a subsequent dose of 
cocaine (Fig. 3-1, B-C). However, repeated exposure to the D1 agonist SKF – 
81 
administered with or without the HDACi, SB – results in a sustained change in 
behavioral plasticity because it was linked to enhanced cocaine reward 6 days after the 
last dose of SKF (Fig. 3-1D).  As a first step towards understanding these phenomena, we 
wanted to identify a chromatin-remodeling mechanisms linked to D1-signaling. Notably, 
previous studies reported D1- agonist or stress induced changes in hippocampal histone 
phosphorylation and phospho-acetylation (Crosio et al., 2003, Chandramohan et al., 
2007) and D2-like antagonist –induced changes in striatal histone phospho-acetylation (Li 
et al., 2004). Importantly, the kinetics of this generalized H3 phosphorylation and 
phospho-acetylation bears resemblance to the induction pattern of immediate-early-genes 
(IEGs) and has been discussed as a “nucleosomal response” in response to receptor 
activation and other stimuli (Thomson et al., 1999).  
To examine the in vivo kinetics of striatal H3 phospho-acetylation (phospho-
serine 10, acetyl-lysine 14, H3pS10acK14) – a dual histone modification enriched in 
neuronal nuclei (Fig. 3-4A) – in response to D1-receptor activation, we treated mice 
either with a single dose, or by repeated, daily injections (2 and 10 days) of SKF, with or 
without SB, and measured striatal H3pS10acK14 levels 30-120 min after the last dose. 
Levels of H3pS10acK14 showed a more than 2.5-fold increase after acute administration 
of SKF82958, and returned to baseline within 120 min after treatment (Fig. 3-4B,C; [FSKF 
30min vs Sal (2,13) = 17.954, p < 0.001]. These changes were specific for the dual 
modification, H3pS10acK14, because levels of the single modification, H3pS10, 
remained unchanged after SKF82958 treatment (Fig. 3-4B). Similar changes were 
observed after repeated exposure for 10 – but not 2 – days of SKF when administered 
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either as single drug or in combination with SB (Fig. 3-4B,C). In contrast, single drug SB 
was indistinguishable from saline (Fig. 3-4B,C). The transient resistance of the histone 
modification machinery to further induction by SKF82958 in the two day treatment 
paradigm (Fig. 3-4B,C) was not due to tolerance, as striatal activation of the prototype 
early response gene, c-fos, was robust at all time points examined (Suppl. Fig. 3-4).  
 To confirm the role of D1-receptors for these dynamic changes in H3S10pK14ac 
for a second rodent species, and in order to test if functional brain circuitry is required, 
we used dissociated rat striatal neuronal cultures that lack midbrain and cortical pre-
synaptic inputs. Treatment of striatal cultures with the D1-agonist, SKF82958 (25 – 50 
µM), induced a significant 1.4 – 2.0 -fold increase in H3pS10acK14 within 30 min (not 
shown) and peaked at 3 hours (Fig. 3-4D, F; *, p<0.05). These changes were specific, 
because levels of global H3 acetylation remained unaffected in cultures treated with SKF 
single drug (Fig. 3-4E). In contrast, addition of  >100 µM SB to the cell culture medium 
resulted in significant increases in H3 acetylation and phosphoacetylation (Fig. 3-4D, E).  
 Finally, given that dopamine-regulated gene expression in striatal neurons 
involves cyclic AMP and NMDA receptor pathways (Konradi et al., 1996), we examined 
the effects of NMDA receptor blockade (MK-801, 2µM) and inhibition of cAMP-
dependent protein kinase A (H89, 20 µM). Indeed, pre-treatment with MK-801 or H89 
prevented or attenuated the up-regulation of H3pS10acK14 after D1-agonist treatment 
(Fig. 3-4F). Taken together, both studies in vitro and in vivo demonstrate that activation 
of dopamine D1 receptors up-regulates bulk chromatin levels of H3pS10acK14 in the 
83 
nuclei of striatal neurons. Furthermore, D1-regulated striatal H3 phospho-acetylation was, 
at least in vivo, not modulated by concomitant treatment with the HDACi, SB.  
 
 
 
DISCUSSION 
Several recent studies identified chromatin remodeling in the striatum  - including the 
regulation of histone acetylation - as an important regulator of stimulant-related plasticity 
and addiction behavior (Kumar et al., 2005, Levine et al., 2005, Kalda et al., 2007, 
Renthal et al., 2007). The present study extends the findings of these earlier studies in 
two ways - first, by demonstrating that histone modification contributes to drug-induced 
changes in gene expression in other parts of the reward circuitry, including the ventral 
midbrain at the level of SN/VTA. Secondly, this report underscores the link between D1- 
dopamine receptor signaling and chromatin modification mechanisms, by showing that 
treatment with D1- agonist (i) is associated with increased sensitization and reward 
behavior upon subsequent exposure to cocaine (ii) induces a generalized, but short-
lasting, nucleosomal response – as defined by the phospho-acetylation of histone H3 in 
bulk chromatin (Thomson et al., 1999) – and (iii) regulates under certain conditions, 
including drug-induced inhibition of class I/II HDAC, histone acetylation and gene 
expression in ventral midbrain chromatin. 
Our study faces several limitations, including the broad molecular action of SB – 
a drug considered a prototype for inhibition of class I/II HDACs but which also interferes 
with the de-acetylation of transcription factors, high-mobility group and other non-
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histones proteins important for chromatin function (Davie, 2003). Therefore, the histone 
deacetylase-containing complex mediating unexpected histone de-acetylation at ventral 
midbrain Bdnf and Th promoters after co-treatment with D1-agonist and SB, in 
conjunction with an up-regulation of corresponding mRNAs - both shown in the present 
study - remains to be identified. In any case, given that Bdnf has trophic actions on 
midbrain dopaminergic neurons (Dluzen et al., 2001, Baker et al., 2005) , the observed 
increase in Bdnf expression may relate, directly or indirectly, to the rise in Th mRNA 
(ventral midbrain) and protein (striatum) in SKF/SB treated animals. Notably, expression 
of Bdnf is dynamically regulated in stress-related models (Lippmann et al., 2007) (and 
references therein)(Berton et al., 2006, Pu et al., 2006).  It will be interesting to determine 
if D1-agonist and HDACi co-treatments affect expression of GDNF and other growth 
factors important for ventral midbrain and dopaminergic neuron function (Chen et al., 
2006).  Notably, recent studies showed that the mood stabilizer, sodium valproate, a 
short-chain fatty acid structurally similar to sodium butyrate, induces Bdnf expression 
and promoter-associated histone acetylation in prefrontal cortex (Fukumoto et al., 2001, 
Bredy et al., 2007). Furthermore, both butyrate and valproate positively regulate a 
number of intracellular effectors of Bdnf signaling, including extra-cellular signal related 
kinases (ERK) pathways and the Ca2+/cAMP dependent transcription factor CREB 
which in turn up-regulate Th expression (Shah et al., 2006, Shaltiel et al., 2007). It is 
possible that transient increases in neurotrophin supply - including those of Bdnf - evoke 
further adaptations in a subset of dopaminergic or other neurons, which then underlie the 
observed changes in cocaine-related behaviors. This scenario would also explain 
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important differences in the timing of the various, drug-induced adaptations, which is 
another limitation of the present study: While the dynamic changes in striatal H3 
phospho-acetylation, and Th and Bdnf expression in ventral midbrain were measured 
within minutes or the first hours after drug treatment, behavioral outcomes were 
monitored up to six days after the last treatments with D1-agonist and HDACi. 
Remarkably, the up-regulation of striatal histone H3 phospho-acetylation after 
activation of D1-signaling (present study) or blockade of D2-like signaling (Li et al., 
2004) is readily apparent on immunoblots from tissue homogenates or extracts, indicating 
that this is a “nucleosomal response” (Thomson et al., 1999) that includes -- but is not 
limited to –  c-fos, c-jun and other immediate early gene promoters (Thomson et al., 
1999, Li et al., 2004). In this context, it is noteworthy that D1-agonist-induced H3 
phospho-acetylation in striatal neurons is completely blocked by the PKA inhibitor, H89 
(Fig. 3-4F). Furthermore, H89 inhibits the nucleosomal response in fibroblasts, via 
functional inactivation of  mitogen- and stress-activated protein kinase 1 (MSK1) 
(Thomson et al., 1999). Notably, recent reports attributed to MSK1 a key regulatory role 
for hippocampal and striatal histone acetylation and phosphorylation (Brami-Cherrier et 
al., 2005, Chwang et al., 2007).  
 The present paper reports that in animals co-treated with D1-agonist and class I/II 
HDACi, cocaine-induced reward behavior is enhanced. It is therefore tempting to 
speculate that the opposite strategy, i.e. treatment with D1-antagonist and a histone 
acetyl-transferase inhibitor (HATi), could perhaps prevent, or attenuate, some of the 
behaviors associated with cocaine reward. Evidence from clinical trials suggest that 
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administration of D1-antagonist drugs to active users may be ineffective or even 
counterproductive (Haney et al., 2001), albeit reduction of cocaine-induced euphoria and 
stimulation had also been reported (Romach et al., 1999).  However, there is evidence 
from animal studies that D1-antagonism may prevent relapse (Alleweireldt et al., 2002, 
Anderson et al., 2003, Sanchez et al., 2003). From the viewpoint of translational 
medicine, it will therefore be of considerable interest to explore whether or not co-
treatment of animals with histone modifying drugs, including HATi or HDACi, alters 
reinstatement or relapse of cocaine-related behaviors.  Finally, it will be important to 
evaluate how chromatin-modifying drugs would affect the developing brain which may 
be particularly vulnerable to stimulant drugs (Schmauss, 2000, Crandall et al., 2004). 
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Figure 3-1.   
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Fig. 3-1.  Changes in cocaine-induced behavior after pre-treatment with D1-agonist and 
HDACi.  (A) Locomotor activity during pre-treatment; Sal followed by SKF (filled 
square?; SB followed by SKF (open square); SB followed by Sal (open circle) and Sal 
followed by Sal (filled circle). Data show locomotor activity for the first 60 min 
following second drug (mean ± S.E.M., N = 8-10 animals/group). Notice that locomotor 
activity was significantly increased in mice treated with SKF±SB when comparing 
activity on day 1 with days 2, 5, 7, or 10 (**, p<0.001)   (B) Locomotor activity before 
and after a single dose of cocaine Animals were placed in activity cages 24 hours after 
the last pre-treatment (see A) and behavior was recorded for t = 190 min total (x-axis). 
Saline injected at t = 75min and cocaine (15 mg/kg) at t = 90 min as indicated by arrows.  
Notice that animals pre-treated with HDACi plus D1-agonist (SB+SKF; open squares) 
show a significant increase in cocaine-induced ambulation when compared to group pre-
treated with D1-agonist only (Sal+SKF, filled circles) (mean ± S.E.M., N = 8-10 
animals/group).  (C) Total ambulation after cocaine (see also B). Notice that pre-
treatment with 100 mg/kg SB+SKF, but not 25 mg/kg SB+SKF, is associated with a 
significant, 4-fold increase in cocaine-induced ambulation, and pre-treatment with SKF 
(Sal+SKF) with a 2.5-fold increase, when compared to mice pre-treated with saline only 
(Sal+Sal). (D, E) Conditioned place preference (D = paradigm 1, E = paradigm 2, see 
Methods), expressed as difference in time spent in cocaine - or saline-associated chamber 
before and after exposure (y-axis). Notice (D) enhanced place preference in animals pre-
treated with Sal+SKF is similar to group treated with SB+SKF, when compared to mice 
pretreated with saline (Sal + Sal). Notice (E) significant cocaine-related place preference 
in group treated with SB+SKF, as compared to single drug SKF.  *, p < 0.05; **, p < 
0.01; n=8-10/group, all data shown as mean ± S.E.M. 
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Fig. 3-2: Treatment with D1 agonist and HDACi is associated with increased gene 
expression in ventral midbrain and histone modification at selected promoter sequences 
 (A) mRNA levels for Th, Bdnf, and B2m from striatum (Stri.) and ventral midbrain 
(Vent. Mid.) of animals treated for 10 days with Sal+SKF or SB+SKF or SB+Sal or 
Sal+Sal and sacrificed 30min after last injection.  Data from qRT-PCR expressed as 
mean ± S.E.M. after normalization to 18S rRNA. Notice that ventral midbrain of animals 
treated with SB+SKF shows significant increases in Th, Bdnf transcripts compared to 
Sal+SKF and Sal+Sal.  In contrast, ventral midbrain B2m levels were significantly 
decreased in SKF+/-SB mice. N=5/group/brain region, *, p<0.05; **, p<0.01. (B) Top, 
schematic presentation of positioning of primer pairs used for ChIP studies at Th, Bdnf 
and B2m promoters (left graph: Th promoter, a-c; middle graph: Bdnf, promoter I, III, IV; 
and right graph, B2m) for amplification of mono-nucleosomal DNA. TSS = transcription 
start site.  Bar graphs showing levels of H3 acetylation at promoter sequences  from 
ventral midbrain of mice after 10 daily treatment with SB+SKF (black bars) or Sal+Sal 
(white bars) as indicated. Animals were sacrificed 30 min after last treatment. Data 
shown as chip-to-input ratios (mean ± S.E.M., N = 5-10 /group). Notice a significant 
decrease in histone acetylation at Th promoter sequence “a” and Bdnf promoter IV 
following SB+SKF treatment. (*, p<0.05). 
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Fig. 3-3: A transient increase in striatal TH after exposure to D1-agonist and HDACi. 
(A) Top: Representative immunoblots from striatum of animals treated for 10 days with 
Sal+SKF or SB+SKF or SB+Sal or Sal+Sal and sacrificed 30min after last injection.  
Blots were labeled with anti-TH (upper band) and anti-histone H4 as loading control 
(lower band).  Bottom: Bar graph showing densitometric quantification of striatal 
immunoblots (mean ± S.E.M., N = 6-10/group).  Notice significant, 2-fold increase in TH 
protein levels in animals treated with SB+SKF compared to saline-treated controls. (B) 
TH immunoblots from ventral midbrain of animals treated with SB+SKF and Sal+Sal 
(same groups as shown in A) reveal no significant differences. (C) Striatal TH 
immunoblots from mice subjected to CPP (see also Fig. 1D), animals were sacrificed 6 
days after last injection of SB+SKF and 24 hours after last dose of cocaine. There is no 
significant difference between mice pre-treated with SB +SKF as compared to pre-
treatment with Sal+Sal (N = 3/group). ** p < 0.01. 
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Figure 3-4. 
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Figure 3-4. D1-receptor signaling regulates H3 phospho-acetylation in striatal neurons. 
(A) Digitized images from striatal section processed for H3p-ac (red, upper panel), and 
NeuN (green, lower panel) immunofluorescence, with DAPI counterstain (blue). Notice 
robust H3p-ac signal in NeuN-positive cells (arrowheads) but absent in non-neuronal 
(NeuN negative) cell (arrow). Images taken at 10 x 63 magnification. (B, C) Histone 
immunoblots and densitometric quantifications from striatum of mice treated with SB 
and SKF as single drug or co-treatments as indicated. Blots in (B) labeled with H3p-ac 
(upper panels) and H3p (lower panels), each with H4 as loading control. Notice robust 
increase in striatal H3 phospho-acetylation both after acute and 10 days of treatment of 
SKF with or without SB. Animals were sacrificed 30 min after last treatment. Bar graphs 
in (C) show densitometric quantifications (mean ± SE) of striatal H3p-ac (N = 3-5/group) 
with comparison to saline-treated control. (D, E) Immunoblot (top) and densitometric 
quantification (bottom) from cultured striatal neurons showing changes in (D) H3p-ac 
and (E) H3ac after 3 hours of treatment with SB and/or SKF. Notice (D) significant 
increase in H3p-ac after 3 hours treatment with SB or SKF, with the highest levels in 
cultures co-treated with SB+SKF. In contrast, (E) up-regulation of H3ac is mediated by 
SB but not SKF.  (F) H3p-ac immunoblots (top) and densitometric quantifications 
(bottom) from cultured striatal neurons treated with D1-agonist (SKF) and/or the NMDA 
receptor antagonist MK801 and the PKA antagonist H89 as indicated.  Notice attenuated 
response to D1-agonist in the presence of MK801 or H89. A-F (*, p<0.05; **, p<0.01). 
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Supplemental Figure 3-1: Histone H4 acetylation at Th and BDNF gene promoters. 
Bar graphs showing levels of H4 acetylation at promoter sequences Th ‘a’  
and Bdnf PIV (see Fig. 2B in main manuscript) from ventral midbrain of mice  
after 10 daily treatments with SB+SKF (black bars) or Sal+Sal (white bars)  
as indicated.  Animals were sacrificed 30 min after last treatment.   
Data shown as chip-to-input ratios (mean ± S.E.M., N = 5 /group).  
 
 
 
Supplemental Figure 3-2: Histone H3 acetylation at Th and BDNF gene promoters. 
Bar graphs showing levels of H3 acetylation (expressed at ChIP-to-input) at  
promoter sequences Th ‘a’ and BDNF PIV (see Fig. 2B in main manuscript) 
from ventral midbrain of mice after 10 daily treatments with SB (25mg/kg) + 
SKF (1mg/kg) (striped bars) or Saline+Saline (Sal+Sal) (white bars) as indicated. 
Animals were sacrificed 30min after the last treatment (mean ± S.E.M., N=4/group). 
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Supplemental Figure 3-3: Steady-state dopamine and DOPAC levels from caudate of 
mice, determined by HPLC. 
 
 
 
 
Supplemental Figure 3-4: Striatal c-fos expression in mice, determined by QRT-PCR. 
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CHAPTER IV: 
Imaging Cocaine-Sensitive Brain Areas Responsive to Chromatin Modifying Drugs 
 The work presented in this chapter is reproduced from a manuscript, currently 
under revision, by Febo et al.  This work was conducted under the collaborative direction 
of Drs. Marcelo Febo, Schahram Akbarian and Craig Ferris and it is with gratitude that I 
reproduce these data for the purposes of this dissertation with minor changes in style and 
text.  My contribution to this work was the experimental execution, data quantification, 
and statistical analysis of the Western blots (Fig. 1).  Drs. Febo and Ferris contributed by 
conducting all BOLD imaging, behavioral studies and associated statististical analyses.  
The manuscript was prepared by Dr. Febo with contributions from Drs. Akbarian and 
Ferris; I contributed a portion of the Materials and Methods section.  
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Abstract 
Inhibitors of histone deacetylases (HDACi) and acetyltransferases (HATi) facilitate or 
impede gene expression in response to drugs of abuse by regulating chromatin packaging. 
Here we tested whether the HDACi sodium butyrate (SB) and the HATi curcumin 
influence changes in brain activation during the initial stage of repeated cocaine 
administration. Four groups of rats were challenged with cocaine during functional 
magnetic resonance imaging (fMRI), (i) those given cocaine for the first time, (ii) those 
receiving cocaine for two days and rats pretreated on each of the two days with either (iii) 
SB or (iv) curcumin 30 min prior to cocaine. Pretreatment with SB increased cocaine-
induced activity in selected regions, including the anterior thalamus, the hippocampus at 
the level of the dentate gyrus and CA3, portions of the amygdala, septum, and 
somatosensory cortex. Curcumin pretreatment, on the other hand, trended towards an 
opposite outcome; reducing brain activation in these regions in comparison to SB. Our 
results underscore a potential role for histone-modifying drugs in modulating cocaine-
induced brain responses and the neuroadaptive changes occurring during the initial 
phases of repeated exposure. Given the known roles of the above brain regions in 
learning, memory, motivation and social recognition, it is possible that chromatin 
remodeling contributes to reinforcing cocaine-associated memories. 
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Introduction 
Psychostimulants and other classes of drugs induce the expression of a variety of early 
response genes. For example, the genes c-fos, c-jun, fosB, junB, zif268 are all elevated in 
neurons of the dorsal and ventral striatum of the rat by a single injection of cocaine or 
amphetamine (Hope et al., 1992, Moratalla et al., 1993, Berke et al., 1998). Protein 
products orchestrated by these genes are presumed to be part of a systematic adaptation to 
the drug (Moratalla et al., 1993), which ultimately determines subsequent neuronal and 
behavioral responses (Canales and Graybiel, 2000). With chronic cocaine exposure, the 
pattern of genes expressed is modified (Hope et al., 1994, Moratalla et al., 1996), 
(Moratalla et al., 1996) an event that may underlie several neurophysiological 
consequences such as alterations in overall electrical excitability of neurons (Yao et al., 
2004, Dong et al., 2006), alterations in receptor-signal transduction mechanisms 
(Gainetdinov et al., 2003), behavioral changes (Hyman, 1999) and further long-term gene 
expression changes (McClung and Nestler, 2003). Knowledge of the molecular steps 
regulating cocaine-induced genes, particularly during the initial stages of drug 
administration may be essential for targeted treatments for addiction.  
A variety of covalent histone modifications, including acetylation, play a key role 
for chromatin function and transcriptional regulation (Verdone et al., 2005) and are 
therefore likely to be play an important role for cocaine-regulated gene expression and 
plasticity. Indeed, acute and chronic exposure to cocaine induces dynamic changes in 
acetylation, phosphorylation and methylation of histones and other chromatin associated 
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proteins in striatum (Brami-Cherrier et al., 2005, Kumar et al., 2005, Levine et al., 2005) 
and prefrontal cortex (Black et al., 2006b, Cassel et al., 2006).  Furthermore, alterations 
of striatal histone acetylation levels by histone deacetylase (HDAC) inhibitor drugs or 
virus-mediated gene delivery strongly affect cocaine-regulated gene expression and 
behaviors (Kumar et al., 2005). Conversely, mice with haploinsufficiency for the 
transcriptional regulator and histone acetyl-transferase (HAT), cAMP-response element 
binding protein (CBP) show an attenuated neurochemical and behavioral response to the 
stimulant (Levine et al., 2005).  
On the basis of these recent findings, the aim of this preclinical study was to 
further explore the effects of chromatin modifying drugs on the brain’s reward and 
addiction circuitry. Specifically, we examined if drug-induced inhibition of two 
functionally opposing classes of enzymes – HDACs and HATs – modulate the animal’s 
response during the initial stages of cocaine-induced changes in brain function. We used 
blood-oxygen-level-dependent (BOLD) fMRI to measure the acute and repeated neural 
response to cocaine in the presence of sodium butyrate (SB), a prototype member of class 
I/II histone deacetylase inhibitor drugs (Davie, 2003) or curcumin, a curry spice extract 
of Curcuma longa acting as CBP-specific HAT inhibitor (Balasubramanyam et al., 2004). 
We report, for the first time, that both SB and curcumin were able to modulate the BOLD 
response to cocaine upon re-exposure, albeit in distinct directions. The HDAC inhibitor, 
SB, enhanced cocaine-induced BOLD activity in specific brain regions, whereas the HAT 
inhibitor curcumin demonstrated an overall opposite action. Interestingly, our findings 
99 
point away from the mesocorticolimbic system for these changes in cocaine sensitivity 
and towards brain areas commonly associated with learning and memory functions. 
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Materials and Methods  
Animals 
Adult Long Evans male rats were purchased from Charles River Laboratories (Charles 
River, MA). Rats were housed in pairs in a temperature and humidity controlled room 
and maintained on a 12L:12D light-dark cycle, with lights off at 1900 hr. Water and 
Purina rat chow were provided ad libitum. Animals were acquired and cared for in 
accordance with the guidelines published in the Guide for the Care and Use of Laboratory 
Animals (National Institutes of Health Publications No. 85-23, Revised 1985) and adhere 
to the National Institutes of Health and the American Association for Laboratory Animal 
Science guidelines. The Institutional Animal Care and Use Committee at the University 
of Massachusetts Medical School approved the protocols used in this study. 
 
Drug preparation and administration 
Cocaine hydrochloride, sodium butyrate acetate (SB) and curcumin extract were all 
purchased from Sigma-Aldrich Co. (St. Louis, MO). Cocaine and SB were dissolved in 
0.9% sterile saline solution. Cocaine was prepared fresh at a dose of 15 mg kg–1 and 
sodium butyrate at 200 mg kg–1 and both were injected i.p. at a volume of 0.1 cc 100 g–1. 
The SB and cocaine administration protocol used in the present study was partly based on 
the one used by Kumar et al (Kumar et al., 2005). According to their results, pretreatment 
of rats with 100 mg kg–1 SB 15-min before cocaine on two days leads to a heightened 
cocaine-induced locomotor response on the second day (Kumar et al., 2005).  For 
imaging experiments, cocaine was injected intracerebroventricularly (ICV) during 
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functional scan acquisition at a concentration of 20 μg in 10 μL artificial cerebrospinal 
fluid (aCSF contained, in mM: 145 NaCl, 2.7 KCl, 10 MgCl2, 12 CaCl2, 20 
Na2HPO4•7H20, pH 7.4).  Curcumin was prepared in 80% dimethylsulfoxide (DMSO) at 
a dose of 30 mg kg–1 and injected i.p. at a volume of 0.25 cc 100 g–1. This dose was 
chosen because a lower dose of orally administered curcumin (10 mg/kg, p.o., in peanut 
oil) given 60 min before testing was shown to cause behavioral alterations (reduced 
immobility) and increase serotonin, norepinephrine and dopamine in the frontal cortex 
and hippocampus of mice (Xu et al., 2005).  Changes in global histone acetylation levels 
after exposure to SB or curcurmin were monitored in neuronal cultures from embryonic 
rat forebrain. As expected, histones became hyperacetylated after SB (5-10 mmol) but 
hypoacetylated after curcurmin (1-5 μmol), in comparison to vehicle (Fig. 4-1).  
Four groups of rats were challenged with cocaine during functional imaging, 
those given cocaine for the first time (group i, 1 day saline-cocaine), those receiving 
cocaine for 2 days (group ii, 2 day saline-cocaine) and rats pretreated on each of the two 
cocaine treatment days with SB (group iii, 2 day SB-cocaine) or curcumin 30 min prior to 
cocaine (group iv, 2 day curcumin-cocaine). For the latter two groups, rats were given an 
i.p. injection of a histone modifying drug and following 30 minutes they were given an 
i.p. injection of cocaine (15 mg kg–1). On day 2, rats were imaged for their response to 
cocaine after pretreatment with vehicle or one of the two histone modifying drugs. They 
were injected and then placed under 2-3% isoflurane anesthesia in preparation for fMRI 
(see below).  Following 30 minutes, all rats were challenged with intra-cerebroventricular 
(ICV) cocaine during functional scanning. This route of injection and dose of cocaine is 
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reported to enhance dopamine neurotransmission and increase blood-oxygen-level-
dependent (BOLD) signal in the mesocorticolimbic system without the cardiovascular or 
respiratory complications caused by systemic administration of cocaine (Febo et al., 
2004).  Injections were made via a plastic 300-μL syringe connected at the end of the 
ICV cannula tubing. Cannula placement was verified prior to cocaine imaging with a 
short anatomical MR scan. Only animals with correct placement were included in the 
study. 
 
Functional magnetic resonance imaging 
All imaging experiments were done in fully awake, unanesthetized male rats. Anesthesia 
(2-3%isoflurane) was used only during the rat setup preceding the experiments (see 
above). Functional MRI experiments were carried out using a multi-concentric dual-coil 
small animal restrainer (Insight NeuroImaging Systems, Worcester, MA). All rats were 
acclimated to the restrainer and the imaging protocol at least a week before functional 
imaging (King et al., 2005). To reduce discomfort from ear and nose bars during both 
acclimation and imaging experiments, a topical anesthetic (10% lidocaine cream) was 
applied to skin and soft tissue in the ear canal and over the bridge of the nose. 
Immediately prior to imaging studies, rats were anesthetized with 2-3 % isoflurane, the 
skull surface was exposed and the landmark suture Bregma located. Lidocaine cream was 
applied around the incision area. A 26-gauge cannula of polyethylene tubing (PE-10: 
inner diameter 0.28 mm, outer diameter 0.61 mm) was lowered into the lateral cerebral 
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ventricle (1 mm caudal to Bregma, 2 mm lateral to the mid-sagittal sinus, and 4 mm 
ventral to dura) and secured to the skull with surgical glue.  
 Magnetic resonance imaging was conducted in a Bruker Biospec 4.7-T/40-cm 
horizontal magnet (Oxford Instrument, Oxford, U.K.) equipped with a Biospec Bruker 
console (Bruker, Billerica, MA U.S.A) and a 20-G/cm magnetic field gradient insert 
(inner diameter = 12 cm, 120-µs rise time). A high-resolution anatomical scan used for 
overlays and multi-subject alignment was collected for 6 minutes using a fast spin echo 
(RARE) pulse sequence (effective echo time = 48 msec, repetition time = 2500 msec, 
field of view = 30 mm, 14 slices, 1.2 mm slice thickness, 2562 data matrix for an in-plane 
resolution of 117 µm2, echo train length = 16, 6 averages). Functional imaging was 
performed with a T2-weighted multi-slice fast spin echo pulse sequence with the 
following parameters: effective echo time = 53.2 msec, repetition time = 2108 msec, 642 
data matrix for an in-plane resolution of 468 µm2, echo train length = 16, echo spacing = 
7 msec. Except for the lower in-plane resolution, the geometrical setup of the functional 
scans exactly matched the anatomical scans for each subject. A single acquisition of all 
14 slices took 8.4 sec. A total of 110 brain images were collected for 15 minutes.  
Cocaine was administered following the initial 35 repetitions (4.9 minutes), which 
corresponded to the pre-cocaine baseline acquisition.  
 
Assessment of cerebrovascular reactivity 
In order to test whether the histone modifying drugs themselves might affect 
cerebrovascular reactivity and consequently affect the BOLD response to cocaine, a 
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separate group of rats were challenged with a 10% CO2 pulse during functional scanning 
(Cohen et al., 2002, Sicard et al., 2003). The release of carbon dioxide from metabolically 
active neuronal tissue triggers dilation of vascular smooth muscle allowing the influx of 
oxygenated blood. Therefore, despite the absence of a neuronal-driving stimulus, cerebral 
blood flow and BOLD-weighted intensity increase in the presence of hypercapnia 
(‘mock’ BOLD activation). Functional imaging was performed using the same pulse 
sequence parameters described above, with the exception that the total acquisition time 
was 8-min (56 repetitions), with two alternating pulses of 10% CO2 given at 1-min blocks 
(7 reps each) between three 2-min baselines (14 reps each). Animals were given an i.p. 
injection of either saline vehicle (n = 5), 80% DMSO vehicle (n = 6), 200 mg kg–1 SB (n 
= 5) or 30 mg kg–1 curcumin (n = 5) during setup, 30 min prior to functional imaging.   
 
Cell cultures 
Cells were prepared from forebrain of E14.5 SASCO SD rat embryos (Charles River).  
Live cells were plated out at 1.2-1.4x106 cells per 100-mm poly-l-lysine coated dishes 
pre-coated with 15ug/ml poly-l-ornithine (Sigma) and 1ug/ml fibonectin (R&D systems), 
treated daily with10ug basic fibroblast growth factor 2 (FGF2 - R&D systems) and 
maintained at 37°C, 5% CO2 and grown in media composed of:  DMEM/F12 + 1% N2 
supplement  + 1% pen/strep + 0.2% Glutamax + 0.01% Glutamine + 0.34% Glucose 
(45% solution, Sigma).   
At DIV5, cells were passaged and plated at 0.8-1.0 x106 cells per pre-coated plate 
and expanded as above for a further 3-4 days (expansion approx 300%). Cells were 
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passaged again, plated at 1.1-1.4 x106, and after 1-2 days, FGF2 was removed. Cells were 
then washed once with media and resuspended in FGF2-free media with or without 
sodium butyrate (5mM, EMD Chemicals, Inc, dissolved in media.) or curcumin (1µM, 
Sigma-Aldrich, dissolved in 100% Ethanol).  48 hours later, SB-containing 
cultures/controls were harvested and media from curcumin-containing cultures/controls 
was replaced with fresh FGF2-free media with or without curcumin (1µM) and 
maintained for an additional 48 hours before harvest.  Cells were harvested by aspirating 
media, rinsing/aspirating briefly with PBS, and snap freezing on dry ice.   
 
Western Blotting 
Frozen rat cells were thawed at 25°C for ~1 min, scraped from culture plates with 
Laemmli homogenization buffer, then incubated at 37°C for 10 min and centrifuged at 
4°C, 13,500 g.  The supernatant was denatured at 95°C for 5 min, then electrophoresed 
on a 10-20% linear gradient Tris-HCl gel (Bio-Rad) and transferred to polyvinylidene 
difluoride (PVDF) membrane (0.2µm pore size, Bio-Rad).  Immunostainings were 
performed with anti-acetyl histone H3 antibody (Chemicon/Upstate #06-599) and, as 
loading control, anti-histone H4 antibody (Chemicon/Upstate, #07-108).  
Immunoreactivity was detected with peroxidase-conjugated secondary antibody (donkey 
anti-rabbit IgG; Amersham) in conjunction with chemiluminesence-based film 
autoradiography (Super-Signal West Dura Extend Reagent, Pierce).  For quantification, 
Quantity One software (Bio-Rad) was used. 
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Behavior testing 
Automated measurements of acute (1 day) and chronic (5 day) locomotor activity were 
taken using an open field box coupled to a digital camera-computer software system that 
quantified rat movement (in cm). The open field box (dimensions in cm: 51 X 51 X 24) 
contained black walls and floor to contrast the rat against its background. Testing was 
done between 0700 to 1100 hrs under dim lighting. The tracking software (Noldus, MA) 
divided the cage into 4 equally spaced quadrants and tracked rat movement based on 
color-contrast. For our studies, 4 groups of rats (n = 8) were tested during 10 min after 
pretreatment with vehicle or chromatin-modifying drugs and then again 10 mins after 
treatment with cocaine. The groups were saline-cocaine, DMSO-cocaine, SB-cocaine and 
curcumin-cocaine. On the first day of testing, rats were given an injection of vehicle or 
chromatin drug and placed into the open field box for 10 mins (same doses and volumes 
as described in drug preparation section above). Thirty mins after the first injection, rats 
were administered an i.p. injection of 15 mg kg –1 cocaine and placed into the open field 
box once again for 10 more mins. This procedure was repeated on a 5th day of testing 
(rats were injected in their homecages on days 2 to 4 following the same drug dosing and 
sequence). Statistical analysis using a Kruskall-Wallis ANOVA by ranks (p < 0.05) was 
performed on the data. The dependent variables were rat movement (in cm) during 
pretreatment and cocaine administration. The independent or grouping variable was 
pretreatment (Sal, DMSO, Curc or SB).  
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Statistical analysis 
Each functional MRI scan was first inspected for excess motion by estimating the 
standard deviation from the image center-of-mass on the Stimulate software (Strupp, 
1996). Animals showing an average displacement exceeding 25% of the total inplane (X-
Y) voxel resolution (>120 μm out of 468 μm) or more than 25% displacement in the slice 
(Z) direction (>300 μm out of 1200 μm slice thickness) were excluded. Time series 
movies were also generated in order to qualitatively confirm the presence of motion (eg, 
continuous timecourse spikes, up-down head movements). Low frequency drift is also a 
common problem in time series fMRI studies and contributes to signal variability.  
Instability in temperature regulation with high performance gradients is one source of the 
problem; however, physiological noise and head motion are also considered to be 
contributing factors to drift (Turner, 1997).  The occurrence of false positive voxels is a 
concern particularly in the simple off-on activation paradigm used in these studies 
comparing the average baseline signal for a given voxel to its average post-stimulation 
signal. To control for this issue, awake rats (n = 4) were exposed to an 18 min long 
imaging protocol mimicking that described above for the fMRI studies.  A 6 min long 
high resolution anatomical scan was followed 2 min later by a 10 min long fMRI time 
series.  During the fMRI time series there was no stimulus presentation. The change in 
MR signal over the 10 min period mimicking the fMRI study without the presentation of 
a stimulus did not differ by more that 2% for any of the four animals studied (see 
Supplemental Fig. 4-1).  The data corroborate our previous work reporting a baseline 
variability in MR signal of approximately 2% in fully conscious animals imaged with an 
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INSL rodent restrainer system and dual coil RF electronics at 4.7T (Brevard et al., 2003, 
Febo et al., 2004, Ferris et al., 2005).  The present data were acquired during 8 or 15-
minute scans and statistical tests performed using the 1st 10-minute block of the time 
series. Scans with prestimulus baseline drifts over 2% were largely due to gradient 
heating from malfunctioning equipment. These scans were excluded from the study. Data 
from a total of 49 rats were originally collected. After applying exclusion criteria, the 
final N was 24 (6 animals per 4 conditions). Scans that passed the initial exclusion 
criteria were aligned to a 3D atlas of the rat brain.   
 Region-of-interest (ROI)-based statistical analysis was done using Medical Image 
Visualization and Analysis (MIVA) software (http://ccni.wpi.edu/cwbench/cwbench-
tiles.jsp). Details of the alignment of scans to the rat brain atlas have been published 
elsewhere (Wu, 2003, Ferris et al., 2005). Each subject was registered to a fully 
segmented electronic rat brain atlas based on 2D textbook images (Paxinos, 1997, 
Swanson, 1999). The alignment process began by outlining the brain perimeters for each 
slice of the anatomy image sets. A marching cubes algorithm with automated 
linearization creates accurate 3D surface shells for each subject (Wu, 2003). This 
enhanced surface generation strategy eliminates the characteristic stair-stepped behavior 
of the marching cubes algorithms while simultaneously increasing the accuracy of the 
geometry representation. These anatomy shells are aligned to the atlas shell. The affined 
registration involved translation, rotation, and scaling in all 3 dimensions, independently. 
The matrices that transformed the subject’s anatomy shells to the atlas space were used to 
embed each slice within the atlas. All transformed pixel locations of the anatomy images 
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were tagged with the segment atlas major and minor regions creating a fully segmented 
representation of each subject. The inverse transformation matrix [Ti]-1 for each subject 
(i) was also calculated.  
Statistical t tests were performed on each subject within their original coordinate 
system. The baseline period was 32 repetitions immediately preceding drug 
administration and the stimulation window was the 32 repetitions following ICV cocaine 
(4.5 minutes for each). Statistical t tests used a 95 % confidence level, two-tailed 
distribution, and heteroscedastic variance assumptions. In order to provide a conservative 
estimate of significance, a false-positive detection-controlling algorithm was introduced 
into the analysis (Genovese et al., 2002). This ensured that the false-positive detection 
rate was below our cutoff of 5 % (Ferris et al., 2005).  Statistically significant pixels were 
assigned their percentage change values (stimulus mean minus control mean) and all 
other pixels were set to zero. Statistical composite maps were created.  
The segmented atlas was cropped and rendered onto 14 slices of 2562 resolution 
corresponding to the field of view of the subjects. The cropped atlas served as a 
segmented composite with coordinates for row, column and slice. A statistical composite 
was created for each group. A Bonferroni correction factor was used to maintain an 
overall uncertainty level of 5% for comparisons between groups. The individual analyses 
were summed within groups. The composite statistics were built using the inverse 
transformation matrices. Each composite pixel location (ie, row, column, slice), 
premultiplied by [Ti]-1, mapped it within a subject voxel (i). A trilinear interpolation of 
the subject’s voxel values (percent change) determined the statistical contribution of the 
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subject (i) to the composite location. The use of [Ti]-1 ensured that the full volume set of 
the composite was populated with subject contributions. The average value from all 
subjects within the group determined the composite value. Due to the inability to align 
each subject at a pixel-level resolution, the composite BOLD response maps may result 
somewhat broader in their spatial coverage than in the individual maps. However, the 
subjects did align very well at a ROI-level resolution. The number of voxels per ROI and 
their corresponding average percent change values were statistically evaluated using a 
non-parametric Neuman-Keuls test (p < 0.05). 
 
Results 
Cocaine-stimulated brain activation: acute versus repeated (1 versus 2-day treatment) 
The total volume of brain activation for each of the four experimental conditions can be 
viewed as 3D models (Fig. 4-2). These 3D volumes of activation are a composite of six 
subjects each and provide a visual representation comparing the difference in the number 
of activated voxels across experimental conditions.  The volumes of activation shown are 
parsed into major brain regions, e.g. cortex, hippocampus, thalamus, amygdala (Fig. 4-3). 
The cortex reveals similar activity across 1 and 2 Day saline/cocaine and 2 Day 
SB/cocaine however showed a dramatic decrease in the curcumin treated group. This 
visual observation is confirmed when the voxel numbers are compared between 
experimental groups as shown on the left column. The curcumin group has a significantly 
lower number of voxels activated with cocaine as compared to the SB group (p<.01).   
The hippocampus and the amygdala show the lowest number of activated voxels in the 2 
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Day saline/cocaine and curcumin groups versus the SB condition (p<.05).  For the 
thalamus, the 1 Day saline/cocaine and 2 Day SB/cocaine groups had a significantly 
higher volume of activation than 2 Day saline/cocaine. In all major brain areas the 
highest median number of activated voxels occurs in the 2 Day SB/cocaine group.   
 BOLD activation maps, co-registered on 2-D, of coronal sections for each of the 
four experimental conditions are shown in Fig. 4-4. These activation maps from the four 
conditions are a composite of six subjects each, fully registered into a 3D rat MRI atlas 
and segmented for volumes of interest (VOI).  An increase in significant BOLD signal 
intensity changes at least 2% above baseline are evident by the volume of colored 
shading (red-yellow) illustrates robust activation across much of the cortical mantle with 
2 Day SB/cocaine.  In comparison, the curcumin treated group revealed much less 
activation in motor (MO) and somatosensory (SSp) cortices.  Further, the accumbens 
(ACB) revealed comparable activity across all experimental conditions.  Interestingly,  
the dorsal thalamus in the area of anterior thalamic nuclei (AM) and medial dorsal 
thalamus (MD) showed evidence of high activity following 2 Day SB/cocaine treatment. 
Lastly, cocaine-induced activation in the cortical nuclei of the amygdala (COA) was 
observed following 2  Day SB/cocaine treatment, but not under the other conditions. 
Brain areas showing a significant difference and opposite response in their BOLD 
signal between SB and curcumin treatments are listed in Table 4-1 and include the 
somatosensory cortex, hippocampus, cortical nuclei of the amygdala, anterior thalamic 
nuclei, septum, periaqueductal gray and substantia nigra.  These eight sites were 
identified from 93 brain areas by comparing the volume of activation (i.e. number of 
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voxels) between all four conditions using a non-parametric, Newman-Keuls test for 
multiple comparisons. Six of these eight sites are presented in Fig. 4-5 showing bar 
graphs of their median (minimum – maximum) voxel number together with their change 
in BOLD signal over time following cocaine injection.  In all cases, there was a greater 
change in BOLD signal over time to cocaine with SB than all other conditions.  BOLD 
signal increases over the first 2-3 min following ICV cocaine and plateaus over the 
remaining 10 min post-stimulus scanning period.         
 
 
 
 
Modulation of mesocorticolimbic BOLD response by cocaine and histone drug 
treatments 
There was no appreciable difference in BOLD activation in the mesocorticolimbic system 
between treatment groups, including in the striatum and ventral midbrain (Fig. 4-6).  
Histone modifying drugs and cerebrovascular reactivity 
Summarized in Fig. 4-7 are the data for the BOLD response to 10% CO2 30 min after 
pretreatments with saline, DMSO or histone modifying drugs. At the present dose, SB did 
not have any significant effect on baseline BOLD contrast in comparison to its 
corresponding vehicle control (saline). This was observed for the number of activated 
voxels and percent BOLD signal change. Similarly, curcumin did not increase BOLD 
signal change in response to CO2 in comparison to its vehicle control group (DMSO). 
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Interestingly, DMSO treated animals showed a greater number of activated voxels than 
saline pretreated animals (p = 0.02), suggesting that it might influence baseline 
cerebrovascular responsivity. Given that there is BOLD increase after curcumin exposure 
due to its vehicle, the observed modulation of the cocaine-related BOLD response in 
curcumin-treated animals could be underestimated and curcumin may even more strongly 
attenuate cocaine-responses than those observed in this study.  
 
Histone modifying drugs on cocaine-stimulated locomotor activity 
Rats given SB and cocaine showed a greater amount of movement within the open field 
cage than any other of the treatment groups (Fig. 4-8b). Statistical tests revealed a 
significant effect of SB treatment on day 1 but not on day 5 (H3,30 = 9.6 p = 0.02 for 
grouping variable). SB rats showed higher locomotor activity than saline pretreated (p = 
0.02) and DMSO rats (p = 0.01).  However, SB-treated rats were not significantly 
different from the curcumin group (p = 0.06). A similar trend, albeit not statistically 
significant, was observed between SB and curcumin rats on day 5 (p = 0.06). There were 
no significant differences in open field activity between the treatment groups tested 
before cocaine administration (Fig. 4-8a). 
 
Discussion 
These studies adopt the notion that addiction is a neuroadaptive response to repeated drug 
exposure and that the changes in brain neurobiology are a consequence of altered gene 
expression due to chromatin modifications, specifically histone acetylation.  At the onset 
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we asked the question whether fMRI could be used to identify cocaine-sensitive areas 
responsive to drugs that interfere with enzymatic acetylation and deacetylation of 
histones.   To this end we tested whether SB, a class I/II HDAC inhibitor, and curcumin a 
CBP/HAT inhibitor could affect cocaine-induced BOLD signal changes.  Our 
experimental designed followed that published by Kumar and colleagues (Kumar et al., 
2005) using a two day cocaine exposure with and without SB.  They reported that 
pretreatment with SB leads to a sensitized locomotor response to cocaine that correlates 
with striatal histone H3 phosphoacetylation. Based on these findings we predicted SB 
would enhance cocaine-induced changes in BOLD signal.  The corollary to this 
proposition predicts that curcumin would reduce cocaine-induced changes in BOLD 
signal. Using a 3D segmented MR atlas we screened 93 brain areas for significant and 
opposite BOLD signal changes to SB and curcumin and identified eight brain areas that 
met these critieria (see Table 4-1).  
 As predicted, SB increased BOLD signal in response to cocaine.  This effect 
appeared to be generalized to most brain areas as shown in the 3D models depicting the 
volume of activation in the whole brain (Fig. 4-2) and major brain areas (Figs. 4-3, 4-4), 
however the mesocorticolimbic dopamine system and the striatum revealed surprisingly 
little difference in BOLD response compared to control rats (Figs. 4-4, 4-5).  Presumably, 
cocaine-induced enhancement in BOLD signal is due to compensatory blood flow to 
metabolically active areas (Stein and Fuller, 1993, Luo et al., 2003, Febo et al., 2004).  
However, it could be argued that the generalized increase in BOLD signal may be 
unrelated to cocaine’s psychostimulant properties; instead, systemic treatment with SB 
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caused an increase in cerebral arterial vascular responsivity.  However, this is unlikely 
since CO2 challenge causes a comparable change in signal intensity and activation profile 
as vehicle (Fig. 4-6).  From these preliminary data, the mechanism of SB-enhanced brain 
activiation response to cocaine remains unclear.  Given that SB interferes with the orderly 
de-acetylation of histones, transcription factors and other molecules (Davie, 2003), the 
drug could alter the normal chromatin response to repeated cocaine exposure, which at 
least at some gene loci is associated with suppressed transcription (Kumar et al., 2005).  
Indeed, the normal BOLD response to repeated cocaine exposure is reduced signal, 
suggesting the brain is less responsive to this psychostimulant (Febo et al., 2005).  Taken 
together, these findings suggest the brain’s initial response to repeated-cocaine exposure 
triggers a desensitization-like mechanism.  By pretreating with SB, this normal 
desensitization response may be attenuated, resulting in an sustained BOLD signal 
despite repeated exposure to cocaine, as observed in the present study.  
In contrast to SB’s effects, curcumin pretreatment decreased the BOLD signal in 
response to cocaine (relative to SB/cocaine treated animals).  However, similar to SB, 
curcumin appeared to affect most brain areas as shown in the 3D models depicting the 
volume of activation in the whole brain (Fig. 4-2) and major brain areas (Fig. 4-3), albeit 
again the mesocorticolimbic dopamine system and the striatum showed surprisingly little 
changes (Figs. 4-4, 4-5). It is unlikely that this blunted BOLD response to cocaine in the 
curcumin-treated animals is due to decreased vascular responsivity since CO2 challenge 
causes a robust change in signal intensity and activation profile (Fig. 4-6).  Indeed, the 
response to CO2 following pretreatment with curcumin exceeds that observed with saline 
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vehicle or SB, suggesting that our study would, if anything, underestimate the true 
inhibition of cocaine-induced brain activation by curcumin. Curcumin targets CPB/p330 
which acetylates histones and possibly other chromatin-associated proteins 
(Balasubramanyam et al., 2004). While curcumin has not yet been tested for its potential 
role in cocaine-induced behavioral sensitization, the present finding that curcumin 
pretreatment decreases BOLD signal to cocaine challenge would predict an inhibitory 
effect on cocaine’s reinforcement and addiction behavior. Conversely, if one of the neural 
characteristics of cocaine sensitization in the rat is a reduced BOLD response with 
repeated cocaine exposure, then the opposite proposition may be made. In this case, 
curcumin, by reducing the BOLD response to cocaine may be accelerating the process of 
cocaine sensitization in the rat. Behavioral experiments should be able to determine this. 
In agreement with our previous findings using fMRI in unanesthetized animals, 
we observed here that repeated cocaine administration resulted in reduced BOLD 
activation. As with our previous work, a present concern is that the neuroadaptations 
observed after 2 days of cocaine largely represent tolerance to the acute effects of cocaine 
and not sensitization per se.  We find that there is an overall reduction in BOLD 
activation in the thalamus with 2 days of cocaine administration and across many brain 
areas after 7 days of cocaine (Febo et al., 2005). This ‘tolerance-like’ result is supported 
by past studies using other in vitro metabolic assays with cellular-level resolution 
(Hammer and Cooke, 1994).  Moreover, Kumar and collegues showed that by day 2 of 
cocaine treatment at the dose used here produces a increased locomotor activity with 
subsequent exposure, a trait reflecting sensitization and not tolerance (Kumar et al., 
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2005).  Thus, reduced BOLD activation with repeated cocaine may be an underlying 
neural trait of sensitization in male rats, however further experiments will be needed to 
rule out the impact of decreases in inhibitory synaptic activity.  
Many of the areas that show a cocaine-induced significant and opposite BOLD 
signal change in the presence of SB and curcumin play significant roles in learning, 
memory (CA3 and dentate gyrus of the hippocampus, anterior nucleus of the thalamus) 
and social recognition (central nucleus of the amygdala, septum), a finding that may 
provide evidence supporting a role for chromatin remodeling in cocaine-induced 
cognitive changes (Browman et al., 1998, Levenson et al., 2004). These same areas also 
form an integrated neural circuit. Lesions of the anterior thalamic nuclei disrupt recall of 
spatial (Mitchell et al., 2002) as well as nonspatial odorant memory (Wolff et al., 2006) 
and lead to reduced Fos-like expression (‘hypoactivity’) in the hippocampal formation 
(Jenkins et al., 2002).  Rats trained on a fear-conditioning paradigm showed increased 
acetylation of H3 but not H4 histones on the CA1 subfield of the hippocampus (Levenson 
et al., 2004).  Treatment with HDACi, including SB and trichostatin A enhanced the 
consolidation of conditioned freezing responses, long-term potentiation in CA1 
pyramidal neurons of hippocampal slice preparations and other memory functions 
(Alarcon et al., 2004, Korzus et al., 2004, Levenson et al., 2004).  Sodium butyrate also 
enhances cocaine sensitization and conditioned place preference (Kumar et al., 2005).  A 
case can therefore be made that during the initial exposure to cocaine, chromatin 
alterations occur in specific brain circuitry to enhance associative learning and memory. 
However, this remains to be tested experimentally. With regards to the somatosensory 
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cortex it is unclear what the role of cocaine-associated chromatin modifications with this 
region may be, however it has been shown to have a significant degree of synaptic 
plasticity in response to cocaine administration in the rat (Drouin and Waterhouse, 2004) 
and in the case of the amygdala, to play an important role in social and olfactory memory 
(Ferguson et al., 2001, Keller et al., 2004).  
At the onset of these studies we anticipated that the mesocorticolimbic 
dopaminergic system would be most affected by cocaine challenge in the face of SB and 
curcumin pretreatments.   However, this was not the case, indeed there was a conspicuous 
absence of any distinct activation profile in the reward circuitry to chromatin modifying 
drugs as shown in Fig 4-5. Conventional wisdom points to these dopamine enriched 
regions as the initial targets for cocaine and its ensuing molecular alterations leading to 
addiction, however it may be that chromatin remodeling in the hippocampal formation 
and associated memory circuits play greater roles than originally anticipated. Indeed, 
electrical stimulation of the ventral subiculum at a specific frequency reinstates cocaine 
self-administration (Vorel et al., 2001) and inhibiting with lidocaine microinjections in 
this region reduced reinstated cocaine seeking behavior (Sun and Rebec, 2003).  
Excitatory synaptic projections from the ventral hippocampus to the ventral tegmental 
area regulate the release of dopamine in other areas of the brain such as the nucleus 
accumbens and medial prefrontal cortex (Legault et al., 2000).  These physiological roles 
of the hippocampus in long-term responding to cocaine could arise from progressive 
alterations in nucleosome structure by chromatin modifications. However, the role of 
hippocampal subregions in cocaine-sensitization needs to be further explored. 
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It is important to mention several caveats of the present experimental design. 
First, in order to avoid the peripheral cardiovascular stimulating actions of cocaine we 
administered the drug at a low ICV dose whereas other studies such as Kumar et al. 
measured behavior in response to 15 mg/kg.  The low dose and direct central 
administration of the drug may have resulted in less activation of regions of the brain 
classically involved in cocaine’s mechanism of action. And it may have also resulted in 
an underestimation of SB and curcumin’s effects on these regions (eg, the dorsal 
striatum, nucleus accumbens). As explained in previous studies, the chosen dose and 
route of administration minimizes the autonomic of cocaine during imaging. Another 
potential caveat was observed from the use of the 80% DMSO vehicle, which resulted in 
increased CO2 stimulated BOLD signal changes. There are reports of 20% increases in 
cerebral blood flow with high doses of DMSO (Kassell et al., 1983) and increases in 
blood oxygen tension in ischemic skin tissue extracts (Myers and Donovan, 1975).  These 
unbeknownst actions of DMSO may have contributed to elevation of the ‘mock’ BOLD 
response to CO2.  
However, the present results are important in that they are the first attempt to tie 
functional changes at the global nervous system level using functional MRI in rats to 
molecular and chromatin-related “epigenetic” level changes. Unexpectedly, brain areas 
commonly associated with learning, memory, motivation and social recognition showed 
the most robust brain activation changes in our paradigms.  Therefore, it is possible that 
dopamine-regulated chromatin remodeling mechanisms, in addition to their effects on 
striatal gene expression (Li et al., 2004, Kumar et al., 2005), regulate cocaine-associated 
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plasticity in widespread brain regions.  Furthermore, based on the present results, we 
predict that curcumin and other HAT inhibitors could emerge as a promising class of 
anti-substance abuse drugs that warrant further exploration in experimental animal 
models of addiction. 
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Figure 4-1. Histone H3 acetylation after HATi and HDACi treatment. (A) Immunoblots 
from neuronal cultures treated  (left) with or without the HDAC inhibitor, sodium 
butyrate (SB, 5mM, 48hrs) or (right) with or without the HAT inhibitor, curcumin (Curc., 
1uM, 4days). Membranes were probed with anti-acetyl-histone H3 (H3ac, upper panels) 
or anti-histone H4 as loading control (H4, lower panels). (B) Densitometric 
quantifications (mean +/- S.E.M.) of H3ac normalized to H4.  Notice (left) SB-induced 
>2.5 fold increase in H3ac compared to untreated control cells. (n=3/group,**, 
F(1,4)=30.83, p=0.005, one-way ANOVA).  Notice also that (right) curcumin treatment 
caused a decrease of H3ac to <75% of control group levels. (n=10/group, *, 
F(1,18)=4.483, p=0.048, one-way ANOVA). 
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Figure 4-2. 3D maps highlighting the volume of brain activation for each of the 
conditions: 1 day cocaine treatment, 2 day cocaine, 2 day cocaine and sodium butyrate 
pretreatment (SB) or 2 day cocaine with curcmin (Curc) pretreatment. 
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Figure 4-3. Number of voxels responsive to cocaine treatment for each condition. 
Treatment groups are: 1 or 2-day cocaine treatment and 2-day treatment in the presence 
of either SB or Curc. Three-dimensional atlas maps on the right present a pictorial view 
of the volume of activation per each region of interest presented in the bar graphs to the 
left. Hue indicates relative BOLD activity from yellow (low) to red (high). Data for voxel 
activations presented as median with minimum-maximum values in parenthesis over the 
corresponding bar graphs. Asterisks indicate significant differences for multiple 
comparisons using a non-parametric Neuman-Keuls test (*p < 0.05, **p < 0.01). 
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Figure 4-4. BOLD signal changes in response to cocaine in rats pretreated with vehicle or 
a histone-modifying drug. 2D rat atlas maps segmented into various regions of interest 
(abbreviated on the left). Colored areas correspond to brain regions that showed 
statistically significant increases in BOLD signal intensity with cocaine administration (p 
< 0.05, corrected for multiple t-tests). Scale bar hue on the right indicates percent 
increase in BOLD (thresholded between 2-11%). Abbreviations: PL, prelimbic area; MO, 
medial orbital area; AL, agranular insula; ACA, anterior cingulate; ACB, accumbens; 
SSp, somatosensory cortex; DS, dorsal striatum; PIR, piriform cortex; LS, lateral septum;  
BNST, bed nucleus of stria sterminalis; VP, ventral pallidum; GP, globus pallidus; AM, 
anteromedial thalamus; LHA, lateral hypothalamic area; DG, dentate gyrus;  MD, 
mediodorsal thalamus; BLA, basolateral amygdala; CA1, CA3, subfields of the 
hippocampus; ENT, entorhinal cortex; COA, central amygdala. 
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Figure 4-5. Number of voxels responsive to cocaine treatment and percent change in the 
BOLD signal over time for each condition. Treatment groups are: 1 or 2-day cocaine 
treatment and 2-day treatment in the presence of either SB or Curc. Data for voxel 
activations presented as median and minimum-maximum values in parenthesis. 
Timecourse plots for the activated voxels are shown under each corresponding bar graph. 
Cocaine was administered ICV at time 0. Asterisks indicate significant differences for 
multiple comparisons using a non-parametric Neuman-Keuls test (*p < 0.05, **p < 0.01). 
Data for percent changes over time presented as mean ± standard error of the mean. 
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Figure 4-6. Three-dimensional atlas maps showing cocaine-induced voxel activations in 
the mesocorticolimbic system for treatment conditions as presented in figures 4-2 and  
4-3. 
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Figure 4-7. BOLD response to 10% carbon dioxide challenge in rats pretreated with 
saline, DMSO, sodium butyrate or curcumin 30 mins before functional imaging. Percent 
BOLD signal change (top left) or volume of activation (top right) are presented as mean 
± standard error of the mean. Gray horizontal bars above timecourse plots denote the time 
when the CO2 pulses were given.  Below are 2D composite atlas maps showing global 
BOLD response to CO2 for each condition. Asterisks indicate significant differences 
between vehicle groups for the number of activated voxels in the thalamus (*p = 0.2, t-
test). 
128 
 
 
 
 
 
 
Figure 4-8. Open field locomotor activity during pretreatment with histone modifying 
drug or vehicle (A) and after cocaine administration (B). Measurements were taken 
during acute (day 1) treatment and following repeated administration (day 5). Asterisk 
denotes statistical differences (p < 0.05). 
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Supplemental Figure 4-1. Control imaging study to assess whether there are BOLD 
signal changes in the absence of any stimulus. The occurrence of false positive voxels is a 
concern particularly in the simple off-on activation paradigm used in these studies 
comparing the average baseline signal for a given voxel to its average post-stimulation 
signal. To control for this issue, awake rats (n = 4) were exposed to an 18 min long 
imaging protocol mimicking that described above for the fMRI studies.  A 6 min long 
high resolution anatomical scan was followed 2 min later by a 10 min long fMRI time 
series.  During the fMRI time series there was no stimulus presentation. Voxels were 
statistically compared before and after the arrow mark for signal intensity changes using 
a t-test (α=0.05, corrected for multiple comparisons). The change in MR signal over the 
10 min period mimicking the fMRI study without the presentation of a stimulus did not 
differ by more that 2% for any of the four animals studied. 
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Table 4-1. Activated voxels in regions of interest of rats treated with chromatin 
modifying drugs or vehicle prior to cocaine. Data representing voxel activations 
presented as median with minimum-maximum values in parenthesis. Asterisks indicate 
significant differences for multiple comparisons using a non-parametric Neuman-Keuls 
test (*p < 0.05, **p < 0.01). Specific comparisons between the treatment groups are 
shown in Figs. 4-3 and 4-5. Differences in septum and periaqueductal gray are in 
comparison to 2 Day SB/Coc. 
Volume of Interest 1 Day 
Saline/Coc 
2 Day 
Saline/Coc 
2 Day 
SB/Coc 
2 Day 
Curc/Coc 
 
somatosensory cortex 
 
90 (44,115)* 
 
98 (61,119)* 
 
149 (105,222) 
 
63 (23,151)** 
 
CA3 hippocampus 
 
17 (10,34) 
 
9 (1,17)* 
 
20 (8,22) 
 
8 (1,18)* 
 
dentate gyrus 
 
13 (6,28) 
 
11 (0,30) 
 
26 (9,47) 
 
3.5 (3,19)* 
 
cortical nucl. amygdala 
 
4 (3,15)* 
 
7 (1,16) 
 
15.5 (3,29) 
 
2 (1,8)** 
 
septum 
 
8 (2,14) 
 
6 (0,10)* 
 
14.5 (7,23) 
 
7.5 (3,12)* 
 
periaqueductal gray 
 
3 (1,12) 
 
3 (0,8) 
 
5 (0,21) 
 
0.5 (0,7)* 
 
anterior nucl. thalamus 
 
2 (0,5) 
 
1 (0,1)* 
 
4.5 (0,3) 
 
1.5 (0,4)* 
 
substantia nigra 
 
3 (1,4) 
 
1.5 (0,7) 
 
3.5 (2,9) 
 
0 (0,9)* 
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CHAPTER V:  
Comprehensive Discussion 
Transcriptional components underlying the cause of depression, drug addiction 
and their therapies have been recognized for many years.  Indeed, the success of these 
treatments, albeit limited, highlights the incredible, plastic nature of the cellular and 
molecular systems within the brain.  However, given the high proportion of patients 
unresponsive to treatment, and the physical, emotional and financial strains associated 
with depression and substance abuse, there is a great need to develop effective, 
mechanism-based treatments.   
Impact of Findings 
This study provides evidence that systemic administration of chromatin 
modifying drugs dramatically alters an animal’s response, on a behavioral and molecular 
level, to environmental- and stimulant drug-induced changes.  Specifically, we have 
shown in three independent studies featuring antidepressant and stimulant drugs that co-
administration with the class I/II HDACi, sodium butyrate, augments their effects in 
comparison to single-drug treatment. 
 In Chapter II, I wanted to test the effects of SB in an animal model of depression 
– that doses sufficient to induce bulk histone acetylation would be associated with an 
antidepressant-like behavioral and molecular response.  This hypothesis included a 
proposal to address the cooperative effects of SB with the selective serotonin reuptake 
inhibitor, fluoxetine as combination therapy is an established clinical tool, particularly in 
cases of resistant forms of depression.  Our work illustrated the potential for the HDACi, 
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sodium butyrate (SB), to augment the effects of the clinical antidepressant, fluoxetine, in 
an animal model of behavioral despair.  Morever, these changes were associated with 
increases in acetylation of bulk chromatin and increased mRNA levels of brain derived 
neurotrophic factor (BDNF) in the frontal cortex.  Given the implications of increased 
corticolimbic BDNF expression by the neurotrophic hypothesis, these data represent 
potential for a new direction in antidepressant therapies.   
In Chapters III and IV, we provided evidence using a broad range of techniques 
that systemic administration of drugs known to affect histone modfication and 
transcription markedly affected cocaine response in rodents.  Sensitization of the 
dopaminergic system by extended treatment with SB and the full D1-agonist, SKF82958 
(SB+SKF) resulted in a dramatic increase in stimulant and reward behavior in response to 
subsequent cocaine challenge.  Moreover, combined administration of SB with SKF was 
associated with changes in chromatin modification and gene expression in ventral 
midbrain and striatum, key regions in dopaminergic transmission putatively involved in 
stimulant-induced reward (Chapter III).  Further, imaging results presented in Chapter IV 
showed brain metabolic responses that were differentially regulated in paradigms 
combining treatment of cocaine with inhibitors of HDAC (sodium butyrate) or HAT 
(curcumin).  Given that SB/stimulant co-administration resulted in activating effects on 
behavior and brain metabolic response across these two studies at brain regions involved 
in the reward circuitry (including striatum and hippocampus) and that activation of the 
BOLD signal by repeated cocaine treatment was attenuated with HATi co-treatment 
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provides exciting promise for the design of future studies addressing stimulant drug 
mechanism and treatment.   
Alternative explanations 
Together, this collective work supports our general hypothesis that histone 
modification has a role in the mechanisms underlying the actions of antidepressant and 
stimulant drugs.  However, it is clear that sodium butyrate, albeit a non-specific HDACi, 
has pleiotropic effects whose mechanism in our experimental paradigms remains largely 
unclear.  Indeed, recent evidence has shown that butyrate exerts its effects via three 
mechanims; i) inhibition of histone deacetylation, including related facilitation of higher-
order chromatin structure ii) induction of cis- and trans-acting butyrate-dependent 
transcription factors for selected genes (via acetylation or physical interaction) and iii) 
regulating expression of genes involved in post-transcriptional mRNA stability (Parab et 
al., 2007).   Moreover, the association of sodium butyrate with bidirectional changes in 
gene expression has been recently extended in a report showing rapid, dynamic effects on 
promoter-region histone acetylation in vitro (Rada-Iglesias et al., 2007).   
Our results in Chapter II on the kinetics of in vivo sodium butyrate-induced 
histone hyperacetylation correspond with these in vitro results (Rada-Iglesias et al., 
2007).  We report that SB administration is sufficient to increase bulk levels of histone 
acetylation in mouse hippocampus and liver, with peak levels of acetylation reached 
30min after injection, and returned to baseline at 60min post-injection (figure 2-2).  This 
general increase in histone acetylation after less than 30min of SB treatment was 
recapitulated in vitro by Rada-Iglesias and colleagues, though interestingly, their data 
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also suggest that the profile of histone acetylation over 2-18hours is differentially 
regulated on a gene-specific basis (Rada-Iglesias et al., 2007).  These comparisons should 
be considered carefully as the impact of histone tail modification is known to be 
dependent on the context in which the histone tail ‘code’ is read – specifically that critical 
factors for unique cellular ‘interpretation’ of the code may not be present in an in vitro 
system.  Thus, future experiments would be needed to accurately determine the butyrate-
induced acetylation kinetics of our plasticity associated genes of interest, including 
BDNF.  These emerging data, particularly those illustrating the dynamic transcriptional 
effects following HDACi administration, may also help to explain why the 
antidepressant-like behaviroal responses we observed following HDACi treatment, both 
behavioral and molecular (Chapter II), could be similarly reported by a researchers 
administering the HATi, curcumin (Xu et al., 2005, Xu et al., 2006, Xu et al., 2007).    
Moreover, the muliple mechanisms attributed to the action of sodium butyrate 
provide additional explanation for the effects we observed following in vivo treatment of 
sodium butyrate.  As reported in chapter III, we observed increases in mRNA levels of 
the catecholamine biosynthesis enzymes, tyrosine hydroxylase (TH) following combined 
treatment of sodium butyrate and SKF.  Yet, chromatin immunoprecipitation studies 
revealed no recognizable pattern of open-chromatin-associated histone acetylation for 
histone H3 or H4 at the TH promoter region.  Interestingly, a recent report has revealed 
that a butyrate-dependent cis-element within the TH promoter region directly regulates 
transcription (Patel et al., 2005).  Moreover, the effects of butyrate on TH may be 
mediated indirectly via altering expression and binding of the TH-transcription factor DJ-
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1 as this factor was shown elevate expression of the dopamine transporter (DAT) 
(Manning-Bog et al., 2007), potentially altering the relative dopaminergic signaling 
capacity of the brain without a concomitant increase in TH mRNA or activity (Goldberg 
et al., 2005).  We plan to test this hypothesis directly by addressing a similar set of 
SB/stimulant experiments in mice deficient for DJ-1; if the enhancing effects of SB on 
stimulant-induced behavior (Chapter III) are mediated via TH, mice deficient for DJ-1 
will reveal a comparatively attenuated response.  As such, our colony of DJ-1 deficient 
mice, a generous gift from Dr. Jie Shen, is currently under expansion. 
Furthermore, increased levels of TH mRNA may have been observed via 
butyrate-mediated increases in post-transcriptional stability of TH mRNA; that increased 
mRNA levels may represent an accumulated of transcript.  To a similar end, a recent 
report has shown dramatic regulatory effects of HDACi treatment on the expression of 
microRNAs (miRNA), short, noncoding RNAs that direct mRNA degradation (Scott et 
al., 2006).  Indeed, although we found no correlative treatment-associated difference in 
the ventral midbrain expression of select miRNAs predicted to target TH (preliminary, 
unpublished experiments), the possibility for changes in an unexamined miRNA or 
miRNA impact on a secondary TH effector-molecules cannot be ruled out.   
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Closing Remarks 
Finally, it is clear that future experiments will be needed to detail the extended 
mechanisms of sodium butyrate on histone modification, transcriptional regulation and 
gene expression.  The results outlined above highlight an HDACi that is by now, very 
close to my heart.   Further, a now-growing record of publications, including those under 
my own surname, provide evidence that the impact of systemic treatment with histone-
modifying drugs, including as sodium butyrate, are sufficient to induce dramatic, 
potentially efficacious effects on a behavioral and molecular level in the context of 
depression and stimulant drug abuse.  Moreover, the effects of co-administration with 
antidepressant and stimulant drugs are particularly exciting in the context of experimental 
pharmacology and the development of novel treatment paradigms.  However, considering 
the broad-action, high relative dosing (mM range) and known pleiotropic effects of 
sodium butyrate, it is my opinion that this drug will likely remain a model for examining 
more specific, novel HDAC inhibitors in the context of a variety of neuropsychiatric 
diseases before generic endorsements for this natural compound are given.   
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